Health-Related Quality of Life, Costs and Treatment of Inflammatory Rheumatic Diseases in Routine Practice : With special emphasis on biological drugs by Laas, Karin
                                                                  
 
Department of Medicine, Division of Rheumatology,  
Helsinki University Central Hospital, Helsinki, Finland 
 
 
 
 
 
 
 
Health-Related Quality of Life, Costs and Treatment of 
Inflammatory Rheumatic Diseases in Routine Practice 
 
 With special emphasis on biological drugs 
 
 
 
 
 
Karin Laas 
 
 
 
ACADEMIC DISSERTATION 
 
 
To be presented, with the permission of the Medical Faculty of the University 
of Helsinki, for public examination in the Faltin Auditorium of the Helsinki 
University Central Hospital on the 3rd of June, 2009, at 12:00 noon. 
 
Helsinki 2009 
 
 2 
 
Supervised by Professor Marjatta Leirisalo-Repo 
   Division of Rheumatology 
   Department of Medicine 
   University of Helsinki 
   Helsinki, Finland 
 
Reviewed by Docent Tuulikki Sokka 
   Department of Medicine 
   Jyväskylä Central Hospital 
   Jyväskylä, Finland 
 
   Docent Antti Malmivaara 
   Finnish Office for Health Technology Assessment  
The National Institute for Health and Welfare  
Helsinki, Finland 
 
Opponent  Associate Professor Ronald van Vollenhoven 
   Rheumatology Unit 
   Department of Medicine 
   Karolinska University Hospital 
   Stockholm, Sweden 
 
 
 
 
 
ISBN 978-9949-18-454-5 (Print) 
ISBN 978-952-10-5506-5 (PDF) 
http://ethesis.helsinki.fi 
Koopia Kolm 
Helsinki 2009 
 
 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
 
 
 
 4 
CONTENTS 
 
LIST OF ORIGINAL PUBLICATIONS..............................................................6 
ABBREVIATIONS............................................................................................7 
ABSTRACT......................................................................................................9 
1. INTRODUCTION ......................................................................................11 
2. REVIEW OF THE LITERATURE..............................................................13 
2.1  Inflammatory joint diseases........................................................13 
2.1.1 Rheumatoid arthritis ............................................13 
2.1.2 Juvenile idiopathic arthritis ..................................14 
2.1.3 Spondyloarthropathies ........................................15 
2.2  Other rheumatic diseases ..........................................................17 
2.2.1 Osteoarthritis.......................................................17 
2.2.2 Fibromyalgia .......................................................18 
2.3  Assessment of HRQoL...............................................................20 
2.3.1 General ...............................................................20 
2.3.2 HAQ ....................................................................21 
2.3.3  SF-36 .................................................................22 
2.3.4  15D ....................................................................23 
2.4  Economic burden of rheumatic diseases....................................23 
2.4.1 General ...............................................................23 
2.4.2 Direct costs .........................................................24 
2.4.3 Indirect costs.......................................................24 
2.4.4 Intangible costs ...................................................25 
2.5  Treatment of RA.........................................................................26 
2.5.1 General ...............................................................26 
2.5.2 Corticosteroids ....................................................26 
2.5.3 Traditional DMARDs ...........................................27 
2.5.4 Biologicals...........................................................29 
2.5.5 Treatment of other inflammatory joint diseases ..30 
3. AIMS OF THE STUDY .............................................................................32 
4. PATIENTS AND METHODS.....................................................................33 
5. RESULTS.................................................................................................42 
 5 
5.1  HRQoL in patients with common rheumatic diseases referred to 
a university clinic (I) ..........................................................................42 
5.1.1 The HRQoL of patients with RA ..........................47 
5.2   Biologicals etanercept and adalimumab already improve HRQoL 
in patients with RA after 3 months of treatment (II)...........................49 
5.3   Clinical outcome and costs of treating chronic arthritis patients 
with infliximab for one year (III).........................................................55 
5.3.1 Clinical outcome..................................................55 
5.3.2 Costs...................................................................57 
5.4   Clinical impact of switching from infliximab to etanercept in 
patients with RA (IV).........................................................................61 
5.4.1 Baseline characteristics of patients.....................61 
5.4.2 Safety of switching from infliximab to etanercept 61 
5.4.3 Clinical outcome of switching from infliximab to 
etanercept......................................................................65 
6. DISCUSSION ...........................................................................................66 
6.1   HRQoL in patients with common rheumatic diseases ...............66 
6.2   Early improvement in the HRQoL of RA patients during their first 
anti-TNF treatment ...........................................................................68 
6.3   Clinical outcome and costs of treating chronic arthritis patients 
with infliximab ...................................................................................70 
6.4   Clinical impact of switching from infliximab to etanercept in 
patients with RA................................................................................71 
6.5   Strengths and limitations of the study (I-IV)...............................74 
SUMMARY AND CONCLUSIONS.................................................................75 
ACKNOWLEDGEMENTS ..............................................................................77 
REFERENCES ..............................................................................................79 
 
 
 
 
 
 
 
 6 
 
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following original publications, referred to in the 
text by their Roman numerals I-IV. The original publications are reprinted with 
the permission of the copyright holders. In addition, some unpublished results 
are presented.                                        
 
I        Laas K, Roine R, Räsänen P, Sintonen H, Leirisalo-Repo M; HUS QoL 
Study Group (2009b): Health-related quality of life in patients with common 
rheumatic diseases referred to a university clinic. Rheumatol Int 29:267–73.  
 
II       Laas K, Peltomaa R, Puolakka K, Kautiainen H, Leirisalo-Repo M 
(2009a): Early improvement of health-related quality of life during treatment 
with etanercept and adalimumab in patients with rheumatoid arthritis in routine 
practice. Clin Exp Rheumatol (Accepted 26.09.2008).  
 
III      Laas K, Peltomaa R, Puolakka K, Kautiainen H, Leirisalo-Repo M 
(2006): Pharmacoeconomic study of patients with chronic inflammatory joint 
disease before and during infliximab treatment. Ann Rheum Dis 65:924-8. 
 
IV      Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M (2008): Clinical 
impact of switching from infliximab to etanercept in patients with rheumatoid 
arthritis. Clin Rheumatol 27:927-32.                                                
 
 
 
 
 
 
 
 
 
 
 7 
ABBREVIATIONS 
 
ACR American College of Rheumatology 
ANA Antinuclear antibody  
ARA American Rheumatism Association  
AS Ankylosing spondylitis 
ASAS Assessment of SpondyloArthritis International Society 
BASDAI BATH ankylosing spondylitis disease activity index  
CI Confidence interval 
CRP C-reactive protein  
DAS28 Disease activity score with 28 joints examined 
DMARD Disease-Modifying Anti-Rheumatic Drug 
EULAR European League Against Rheumatism 
ESR Erythrocyte sedimentation rate  
FM Fibromyalgia  
HAQ Stanford Health Assessment Questionnaire  
HLA Human leucocyte antigen 
HRQoL Health-related quality of life  
ILAR International League of Associations for Rheumatology  
IQR Interquartile range 
JIA Juvenile idiopathic arthritis 
MCID Minimally clinically important difference 
MCP Metacarpophalangeal joint 
MID Minimally important difference  
MTX Methotrexate  
NSAID Nonsteroidal Anti-Inflammatory Drug  
OA Osteoarthritis 
PIP Proximal interphalangeal joint 
PSA Psoriatic arthritis  
QALY Quality-adjusted life year 
QoL Quality of life  
RA Rheumatoid arthritis 
RAND-36 The RAND 36-Item Health Survey 1.0 
RaQoL Rheumatoid Arthritis Quality of Life (questionnaire) 
 8 
RCT Randomized control trial 
ReA Reactive arthritis 
RF Rheumatoid factor 
RTX Rituximab 
SD Standard deviation 
SF-36  The Medical Outcomes Study Short Form 36 item 
Health Status Survey Questionnaire 
SPA Spondyloarthropathy 
TNF Tumour necrosis factor 
VAS        Visual analogue scale  
 
 
 
 
 
 
 
 
 
 
 
 9 
ABSTRACT 
 
Rheumatoid arthritis (RA) and other chronic inflammatory joint diseases 
already begin to affect patients’ health-related quality of life (HRQoL) in the 
earliest phases of these diseases. In treatment of inflammatory joint diseases, 
the last two decades have seen new strategies and treatment options 
introduced. Treatment is started at an earlier phase; combinations of disease-
modifying anti-rheumatic drugs (DMARDs) and corticosteroids are used; and 
in refractory cases new drugs such as tumour necrosis factor (TNF) inhibitors 
or other biologicals can be started.  
 
In patients with new referrals to the Department of Rheumatology of the 
Helsinki University Central Hospital, we evaluated the 15D and the Stanford 
Health Assessment Questionnaire (HAQ) results at baseline and 
approximately 8 months after their first visit. Altogether the analysis included 
295 patients with various rheumatic diseases. The mean baseline 15D score 
(0.822, SD 0.114) was significantly lower than for the age-matched general 
population (0.903, SD 0.098). Patients with osteoarthritis (OA) and 
spondyloarthropathies (SPA) reported the poorest HRQoL. In patients with RA 
and reactive arthritis (ReA) the HRQoL improved in a statistically significant 
manner during the 8-month follow-up. In addition, a clinically important change 
appeared in patients with systemic rheumatic diseases. HAQ score improved 
significantly in patients with RA, arthralgia and fibromyalgia, and ReA. 
 
In a study of 97 RA patients treated either with etanercept or adalimumab, we 
assessed their HRQoL with the RAND 36-Item Health Survey 1.0 (RAND-36) 
questionnaire. We also analysed changes in clinical parameters and the HAQ. 
With etanercept and adalimumab, the values of all domains in the RAND-36 
questionnaire increased during the first 3 months. The efficacy of each in 
improving HRQoL was statistically significant, and the drug effects were 
comparable. Compared to Finnish age- and sex-matched general population 
values, the HRQoL of the RA patients was significantly lower at baseline and, 
despite the improvement, remained lower also at follow-up. Our RA patients 
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had long-standing and severe disease that can explain the low HRQoL also at 
follow-up.  
 
In a pharmacoeconomic study of patients treated with infliximab we evaluated 
medical and work disability costs for patients with chronic inflammatory joint 
disease during one year before and one year after institution of infliximab 
treatment. Clinical and economic data for 96 patients with different arthritis 
diagnoses showed, in all patients, significantly improved clinical and 
laboratory variables. However, the medical costs increased significantly during 
the second period by €12 015 (95% confidence interval, 6 496 to 18 076). 
Only a minimal decrease in work disability costs occurred – mean decrease 
€130 (-1 268 to 1 072). 
 
In a study involving a switch from infliximab to etanercept, we investigated the 
clinical outcome in 49 patients with RA. Reasons for switching were in 42% 
failure to respond by American College of Rheumatology (ACR) 50% criteria; 
in 12% adverse event; and in 46% non-medical reasons although the patients 
had responded to infliximab. The Disease Activity Score with 28 joints 
examined (DAS28) allowed us to measure patients’ disease activity and 
compare outcome between groups based on the reason for switching. In the 
patients in whom infliximab was switched to etanercept for nonmedical 
reasons, etanercept continued to suppress disease activity effectively, and 1-
year drug survival for etanercept was 77% (95% CI, 62 to 97). In patients in 
the infliximab failure and adverse event groups, DAS28 values improved 
significantly during etanercept therapy. However, the 1-year drug survival of 
etanercept was only 43% (95% CI, 26 to 70) and 50% (95% CI, 33 to 100), 
respectively.    
 
Although the HRQoL of patients with inflammatory joint diseases is 
significantly lower than that of the general population, use of early and 
aggressive treatment strategies including TNF-inhibitors can improve patients’ 
HRQoL effectively. Further research is needed in finding new treatment 
strategies for those patients who fail to respond or lose their response to TNF-
inhibitors. 
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1. INTRODUCTION 
 
Musculoskeletal disorders impose a considerable burden upon society 
because of long-term morbidity, disability, and costs. Among musculoskeletal 
diseases, rheumatoid arthritis (RA) leads to patients’ incurring a significantly 
higher individual economic burden for society than does osteoarthritis (OA), 
for example, largely because of indirect costs (Maetzel et al. 2004). These 
indirect costs arise from sick-leaves, part-time work, and early retirement. The 
peak rate for work disability is at two years after symptom onset, ranging from 
23% to 42% (Barrett et al. 2000). Several studies have shown that predictors 
of future productivity loss in early RA are a low education level, older age, 
severity of RA, and a disability score ≥ 1 measured by the Stanford Health 
Assessment Questionnaire (HAQ) (Puolakka et al. 2005). 
 
Living with a chronic disease affects many aspects of an individual’s life 
including health-related quality of life (HRQoL). In musculoskeletal diseases, 
the deterioration of HRQoL is often a result of long-term pain and reduced 
physical functioning. In a study of multiple musculoskeletal diseases, the 
worst HRQoL was in patients with OA, osteoporosis, RA, and fibromyalgia 
(Picavet and Hoeymans 2004). In patients with RA, the HRQoL is already 
affected in the early phases of the disease. Those with early RA report the 
greatest deterioration in bodily pain and in physical functioning, involving 
limitations in activities of daily living and work (West and Jonsson 2005).  
 
The contemporary treatment strategies of RA aim to achieve remission or low 
disease activity and include early and aggressive treatment with disease-
modifying anti-rheumatic drugs (DMARDs) as mono or combination treatment, 
and use of low-dose corticosteroids or biologicals or both in patients with 
severe disease unresponsive to conventional DMARDs. Randomized control 
trials (RCTs) have demonstrated the efficacy of tumour necrosis factor (TNF) 
inhibitors in reducing disease activity and slowing radiological progression 
(Moreland et al. 1997, Lipsky et al. 2000, Breedveld et al. 2006). In addition, 
recent studies have demonstrated the ability of TNF-inhibitors to improve RA 
patientsۥ  HRQoL (Han et al. 2007, Kimel et al. 2008, Mathias et al. 2000, 
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Mittendorf et al. 2007). The high costs of biologicals compared with 
conventional DMARDs, however, increase the costs of RA treatment 
substantially. Cost-effectiveness studies suggest that costs associated with 
use of TNF-inhibitors may be acceptable in relation to the benefits obtained 
(Russell 2008). 
 
Although TNF-inhibitors have demonstrated good capability to suppress 
disease activity effectively, approximately one-third of patients still fail to 
respond (Lipsky et al. 2000, Weinblatt et al. 1999). Several studies have 
reported that switching from one TNF-inhibitor to another in the case of 
response failure can be a good alternative (Buch et al. 2007, Hyrich et al. 
2007, Nikas et al. 2006). 
 
The primary aim of our study was to follow patients with different rheumatic 
diseases during treatment with TNF-inhibitors and to evaluate their HRQoL, 
their costs, and in patients who were switched to the second TNF-inhibitor, 
also their clinical outcome. Another focus of our study was to assess the 
HRQoL of patients with different musculoskeletal disorders referred for the 
first time to Helsinki University Central Hospital and to evaluate any change in 
HRQoL after 8-month routine treatment. 
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2. REVIEW OF THE LITERATURE 
            
 
2.1 Inflammatory joint diseases 
 
2.1.1 Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of 
unknown etiology that affects predominantly the synovial joints but can also 
induce extraarticular manifestations. RA has worldwide distribution with a 
prevalence estimated at 0.5 to 1% in studies across Europe, North America, 
Asia, and South Africa (Silman and Hochberg 2001). In Finland, the 
prevalence of clinically significant RA is 0.8% of the adult population. In 1995 
the annual incidence was a reported 34 per 100 000 (Aho et al. 1998, 
Kaipiainen-Seppanen and Aho 2000). Women are affected two to three times 
more often than men, and RA incidence increases with age. 
 
RA onset may be acute, subacute, or insidious, with the last course being the 
most common. The clinical course varies from a benign monocyclic to more 
frequent long-standing progressive disease that causes joint destruction even 
during the first years of the disease. RA commonly affects symmetrically the 
small peripheral joints of the hands and feet like the metacarpophalangeal, 
proximal interphalangeal, and metatarsophalangeal joints, but also the wrists, 
knees, cervical spine, glenohumeral joints, and hips. 
 
RA is a systemic disease that may also affect other organs and tissues. The 
most common extraarticular manifestations include subcutaneous rheumatoid 
nodules, vasculitic skin lesions, secondary Sjögren syndrome, pericarditis, 
pleuritis, pulmonary interstitial fibrosis, mononeuritis multiplex, amyloidosis, 
and Felty’s syndrome (Harris et al. 2005, Turesson et al. 2002). 
 
The inflammation and destructive changes in joints lead to functional 
disability. This results in impaired social functioning, and in diminished work 
capacity or total work disability in patients of working age. The American 
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College of Rheumatology (ACR) has provided classification criteria for RA 
(Table 1) (Arnett et al. 1988).        
 
   
Table 1.  American College of Rheumatology classification criteria of 
rheumatoid arthritis. For the diagnosis of RA, a patient should have at least 
four of the seven criteria. Criteria 1-4 must have been present for at least 6 
weeks. 
 
1. Morning stiffness (1 hour or more) 
2. Arthritis in three or more joint areas 
3. Arthritis of the hand joints (PIP, MCP, wrist) 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Serum rheumatoid factor 
7. Radiographic changes in a hand or wrist joint or both 
PIP, proximal interphalangeal joint; MCP, metacarpophalangeal joint. 
 
 
2.1.2 Juvenile idiopathic arthritis 
 
Juvenile idiopathic arthritis (JIA) begins before the age of 16 and is defined as 
a sterile inflammation of at least one joint lasting minimally for 6 weeks, and 
for which there is no defined diagnosis (Fink 1995). According to the 
classification proposed by the International League of Associations for 
Rheumatology (ILAR), JIA has seven clinical subtypes: oligoarthritis, 
seronegative polyarthritis, seropositive polyarthritis, systemic arthritis, 
enthesitis related arthritis, psoriatic arthritis, and undifferentiated arthritis 
(Petty et al. 2004). 
 
JIA is the most common rheumatic disease in childhood. Prevalence 
estimates of JIA in children under age 16 published in the last 20 years in 
Scandinavian countries and in Estonia were 84 to 148 per 100 000 (Pruunsild 
et al. 2007, Gare and Fasth 1992, Moe and Rygg 1998). In other European 
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countries, the USA, and Canada, prevalence has ranged from 40 to 160 per 
100 000 (Silman and Hochberg 2001). 
 
Age of onset depends greatly on subtype. Among girls the incidence is 
highest between ages 1 and 3 years. Oligoarthritis is the most common 
subtype, comprising more than half of the JIA cases. The best long-term 
outcome has been associated with persistent oligoarthritis and the worst with 
rheumatoid factor (RF) -positive polyarthritis. Studies in the last 10 years have 
shown that only 40 to 60% of patients had inactive disease or were in clinical 
remission at follow-up. Despite the persistent disease activity in most patients 
with JIA, functional outcome has been reported as good at follow-up, with only 
2 to 10% of patients suffering serious functional disability (Ravelli and Martini 
2007).  
 
 
2.1.3 Spondyloarthropathies 
 
The spondyloarthropathies (SPAs) comprise five subtypes: ankylosing 
spondylitis (AS), reactive arthritis (ReA), psoriatic arthritis (PSA), enteropathic 
arthritis, and undifferentiated arthritis. AS is the most frequent subtype, being 
more prevalent than are undifferentiated arthritis and PSA, while enteropathic 
arthritis and ReA are even less prevalent. SPAs share similar features of 
disease, such as a typical pattern of peripheral arthritis affecting 
asymmetrically the lower limbs, absence of RF, and subcutaneous nodules 
typical to RA, a tendency toward radiographic sacroiilitis, familial aggregation, 
and association with human leucocyte antigen (HLA) B27. 
 
2.1.3.1 Ankylosing spondylitis  
 
AS is an HLA-B27-associated chronic inflammatory disease affecting the 
spine, sacroiliac joints, peripheral joints, and enthesis. AS predominantly 
appears in the second or third decade of life and its prevalence is 0.5% (Gran 
and Husby 1993). Clinically, AS is more common in males, with a male-to-
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female ratio of 2:1 to 3:1. Most often the first clinical sign of AS is low back 
pain in the gluteal region, associated with a feeling of low back stiffness that is 
worse in the morning and can awaken the patient at night. The pain can 
radiate to the iliac crest, greater trochanteric region or down the dorsal thigh 
and is relieved by physical activity.   
 
In the clinical picture, low back pain is often accompanied by chest pain, 
extra-articular tenderness, and arthritis of the hip, shoulder or knee joints. The 
common sites of extra-articular tenderness caused by enthesitis are the 
costosternal junctions, spinous processes, iliac crests, greater trochanters, 
ischial tuberosities, tibial tubercles, or heels. Acute anterior uveitis or 
iridocyclitis can occur in 25 to 30% of AS patients at some time in the course 
of the disease.  
 
The diagnosis of AS is based on clinical features. A definite diagnosis is 
usually established by radiographic evidence of bilateral sacroiliitis that is very 
seldom present in the early stages of disease. Therefore, presence of low 
back pain and positive family history for AS are critically important for 
diagnosis (Harris et al. 2005). 
 
2.1.3.2 Reactive arthritis 
 
ReA can be defined as a sterile synovitis that is preceded by 4 to 8 weeks by 
an infection usually in the gastrointestinal or genitourinary tract. The clinically 
diagnosed infection may involve diarrhea or nongonococcal urethritis. It can 
also be diagnosed by identifying the bacteria that most often cause ReA: 
Chlamydia, Salmonella, Shigella, Yersinia, or Campylobacter. In addition, 
other infectious agents such as Clostridium, Mycoplasma, and Ureaplasma 
have been suspected as triggering infections (Leirisalo-Repo 2005). 
 
ReA is typically a disease of young adults, mean age 20 to 30 years. In ReA 
that occurs after a genitourinary infection, males are more affected. After a 
gastrointestinal infection, males and females are at similar risk for ReA.  The 
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clinical pattern of ReA is asymmetrical arthritis in the lower limbs affecting one 
or several joints. Extraarticular manifestations can occur, such as urethritis, 
balanitis, conjunctivitis, iritis, entesopathy, low back pain, or skin syndromes 
such as keratodermia blenorrhagica or erythema nodosum. ReA diagnosis 
can be supported by laboratory tests that identify the arthritis-causing 
bacteria. When positive, they support a diagnosis of ReA but when negative, 
ReA cannot be ruled out.  
 
 
2.2 Other rheumatic diseases 
 
2.2.1 Osteoarthritis 
 
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by 
erosions of the articular cartilage, marginal osteophytes, subchondral 
sclerosis, and biochemical and morphological changes in the synovium and 
joint capsule (Harris et al. 2005).   
 
OA is the most frequent rheumatic disorder, and its occurrence is increasing 
with aging populations. Prevalence estimates of OA vary widely depending on 
the OA localisation and on diagnosis methodology. One of the largest OA 
prevalence surveys has been conducted in the USA – the Health Examination 
Survey and First National Health and Nutrition Examination Survey (Lawrence 
et al. 1998). Based on radiographic criteria, the prevalence of OA in the USA 
among adults aged 25 to 74 was 32.5 for the hands, 22.2 for the feet, and 3.8 
per 100 for the knees. Prevalence increased similarly with age among men 
and women. In the age group 55 to 74, the corresponding prevalence ratios 
were 70% for the hands, 40% for the feet, 10% for the knees, and 3% for the 
hips (Silman and Hochberg 2001).  
 
The most important symptom of OA is joint pain that can be typically use-
related in the beginning of the disease, and in advanced OA can persist for 
several hours. Other OA symptoms are joint stiffness, tenderness, loss of 
movement, and joint instability.  The diagnosis of OA is usually based on 
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interviews and clinical investigations. Radiographic investigations may be 
necessary to predict the evolution of the disease, to provide a baseline picture 
of the structural damage, and to indicate specific treatments. Laboratory tests 
are useless for diagnosing OA but can be helpful in excluding other 
diagnoses. 
 
Management of OA includes pharmacological and nonpharmacological 
interventions, and in cases of severe joint destruction and pain, orthopaedic 
surgery. Nonpharmacological interventions mean patient education, weight-
loss, exercise, orthoses, topical applications of heat or cold, use of canes and 
other interventions. Pharmacological interventions can be divided into 
symptomatic therapy and potentially disease-modifying therapy. Although 
acetaminophen (paracetamol) is the first choice of symptomatic therapy 
because of its safety and efficacy, the most commonly prescribed medications 
for OA patients are the nonsteroidal anti-inflammatory drugs (NSAIDs). Oral 
NSAIDs should be maintained at the lowest effective dose for the shortest 
duration (Zhang et al. 2007). The potentially disease-modifying therapies (for 
example, glucosamine, chondroitin sulphate, intraarticular hyaluronan) give a 
moderate clinically significant treatment benefit with low toxicity when 
compared to placebo, but no clinically important structure modification has 
been established (Towheed et al. 2005). Surgical interventions usually include 
osteotomy or joint replacement. Osteotomy can be effective in relieving pain 
and delaying the need for joint replacement. Joint replacement surgery is 
considered most frequently with OA of the hip or knee and should be 
considered in patients with radiographic evidence of OA, refractory pain, or 
disability (Jordan et al. 2003, Zhang et al. 2005).  
 
 
2.2.2 Fibromyalgia 
 
Fibromyalgia (FM) is a chronic pain syndrome affecting 0.5 to 2.0% of the 
general population (Silman and Hochberg 2001). In addition to pain, patients 
with FM complain about fatigue, sleep problems, stiffness, headaches, and 
psychological distress. FM is more prevalent in women: in a study from the 
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USA, 3.4% compared to 0.5% of men (Wolfe et al. 1995). For research 
purposes, the ACR has published classification criteria for FM that require the 
presence of widespread pain in combination with 11 or more tender points on 
examination of 18 anatomical sites. The diagnosis has to be made according 
to an interview and clinical examination because laboratory tests and 
radiographic examinations fail to show any abnormalities in patients with FM. 
The overall health status of these patients is poorer than that of the general 
population or patients with other conditions widely accepted as causing 
impairment (Hoffman and Dukes 2008).  
 
Treatment of FM is focused on reducing pain, improving sleep, restoring 
physical functioning, maintaining social functioning, and improving emotional 
balance. According to European League Against Rheumatism (EULAR) 
recommendations, management of FM includes both pharmacological and 
nonpharmacological treatment. Effective nonpharmacological methods are 
heated pool treatment, individual exercise programs, and cognitive 
behavioural therapy. Pharmacological treatments include tramadol, 
paracetamol, and weak opioids for the management of pain. In addition, 
various anti-depressants can be used to reduce pain and improve function 
(Carville et al. 2008). 
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2.3 Assessment of HRQoL 
 
2.3.1 General 
 
Quality of life (QoL) is a broad-ranging concept that incorporates health 
states, as well as satisfaction with work, leisure time, level of independence, 
social relationships, and environment (Carr et al 1996). The World Health 
Organization (WHO) has defined QOL as an “individual’s perception of their 
position in life in the context of the culture and value systems in which they 
live and in relation to their goals, expectations, standards and concerns” 
(Anonymous 1995). HRQoL is a multidimensional concept that encompasses 
an individual’s physical, emotional, and social components associated with 
his/her medical condition or its treatment (Khanna and Tsevat 2007).  
 
Interest in measuring HRQoL has increased markedly in recent decades. With 
advances in medical science and technology, an increasing number of people 
live contentedly with chronic diseases and disabilities. This change in the 
morbidity profile has evoked the need to evaluate the outcome of different 
treatments according to the patientsۥ perspective.  
 
HRQoL can be measured either with disease-specific or generic 
measurement tools.  The generic instruments allow comparisons between 
patient groups with different diagnoses, whereas the disease-specific 
instruments give information about only one certain disease and its effect on 
health. Disease-specific instruments are, however, more sensitive to important 
health status differences essential for a particular disease. They are therefore 
successfully used for measuring results of specific treatments.  A well-known 
example of a disease-specific instrument is the Rheumatoid Arthritis Quality of 
Life (RaQoL) questionnaire; this is the first patient-completed instrument 
specially designed for use with RA patients (de Jong et al. 1997). The RaQoL 
has proven able to distinguish better than generic instruments between 
different RA groups based on disease severity (Marra et al. 2005). The 
RaQoL questionnaire is easy to use, has a short administration time, and it 
deals with items and issues important for patients with RA (Russell 2008). 
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The generic instruments can be divided into profile and single index score 
measures.  Profile measures describe the health state according to various 
physical and emotional dimensions such as physical functioning, bodily pain, 
general health, social functioning, and other dimensions. A well-known 
example of a generic instrument is the widely used Medical Outcomes Study 
Short Form 36 item Health Status Survey Questionnaire (SF-36). The single 
index score instruments produce a single value (utility score) on a 0-1 scale 
that provides an overall picture of the level of HRQoL and changes in it. Utility 
values are necessary for calculating the Quality-Adjusted Life Years (QALYs), 
developed to combine the quantity and quality of life into a single measure. 
The cost per QALY can be estimated and compared among different 
treatments in economic analyses. Utilities are derived from health status by 
assigning population-based weights based on preferences for health states, 
and are usually expressed on a continuum from perfect health (1) to death (0), 
although health states worse than death can also be evaluated (Russell 
2008). Generic single index score instruments include the EuroQol-5D, Health 
Utilities Index Mark III, SF-6D (derived from RAND-36/SF-36), and the 15D. 
 
 
2.3.2 HAQ  
                 
 The Stanford Health Assessment Questionnaire (HAQ) was originally 
developed as one of the first self-report, functional status measures for use in 
RA patients and has become one of the most often used instruments in other 
musculoskeletal disorders, as well (Fries et al. 1980). Although the HAQ is not 
disease-specific, it was validated in RA patients. 
  
The HAQ is a measure of physical disability that assesses a respondent’s 
ability to complete everyday tasks in dressing and grooming, rising, eating, 
walking, personal hygiene, reach, grip and other activities. Each of these 
areas is assigned a section score that is further adjusted to account for the 
use of any aids or devices or any help from another person. These scores are 
then summed and averaged to give an overall score between 0.0 (best 
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possible function) to 3.0 (worst function). Besides the statistical significance of 
the results, the clinical importance of the results should also be reported to 
avoid over-reporting of conclusions (van Tulder et al. 2007). According to 
several studies, the minimally clinically important difference (MCID) of the 
HAQ in RA patients ranges from 0.09 to 0.19 (Pope et al. 2009, Kosinski et al. 
2000, Marra et al. 2005). 
 
The HAQ has been shown to be useful in studies of short-term response to 
treatment (Bruce and Fries 2003). Physical disability measured by the HAQ 
depends on the disease stage. In early RA, HAQ disability is influenced by 
disease activity and in late disease also by the irreversible joint damage. In 
RA of longer duration, therefore, the HAQ score is less responsive to change 
(Welsing et al. 2001, Aletaha and Ward 2006). The Finnish version of the 
HAQ has been available since the first half of 1990s (Hakala at al. 1994). 
 
 
2.3.3  SF-36 
 
The SF-36 is a well-validated generic health status measure used in health 
surveys in the general population as well as in various populations with 
different diseases. The 36 items in the questionnaire are grouped into 8 multi-
item subscales measuring physical functioning, role limitations due to physical 
problems, bodily pain, general health perceptions, vitality, social functioning, 
mental health, and role limitation due to emotional problems. For each 
subscale a score is calculated with possible values from 0 to 100, where low 
scores indicate poor health (Ware and Sherbourne 1992). In a study by 
Kosinski et al. (2000), mean changes in the SF-36 domain scores were 
calculated for patients with RA at one level of improvement in patient-reported 
pain or global assessment of disease activity. For pain, these ranged from 1.9 
to 10.8 and for global assessment of disease activity from 4.2 to 21.0. Earlier 
analyses have indicated that improvements of 5 to 10 points in SF-36 
domains represent an MCID in RA patients (Wolfe et al. 2005).  
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SF-36 and the RAND 36-Item Health Survey 1.0 (RAND-36) contain identical 
items. However, their scoring algorithms to derive physical and mental health 
summary scores and the general health subscale, and scoring of the second 
pain item (interference with normal work) differ slightly (Cunningham et al. 
2003). 
 
 
2.3.4  15D 
 
The 15D (Sintonen 2001) is a generic, 15-dimensional, standardised, self-
administered measure of HRQoL that can serve both as a profile and as a 
single index score measure. The valuation system of the 15D is based on an 
application of the multiattribute utility theory. A set of utility or preference 
weights, elicited from representative samples of the general population 
through a 3-stage valuation procedure, is part of an additive aggregation 
formula to generate the utility score, i.e., the 15D score (single index number) 
covering all the dimensions. A change in score of ≥ 0.03 is considered 
clinically significant or important (Sintonen 1995). For most of the important 
properties, the 15D compares favourably with other instruments of its kind 
(Stavem 1999, Hawthorne et al. 2001, Sintonen 2001), and the instrument has 
thus been widely used in patients with different diseases in different countries.  
 
 
2.4      Economic burden of rheumatic diseases 
 
2.4.1 General  
 
The economic burden of four major rheumatic diseases: OA, osteoporosis, 
RA, and low back pain, is substantial both for the individual but also for the 
health-care and social-care system. Musculoskeletal diseases are the most 
common cause of long-term pain and physical disability, and their prevalence 
is growing because of the increase in life expectancy and ageing populations. 
The burden of these diseases relates also to the cost of the disease to the 
health care system of the country (Reginster 2002, Woolf and Pfleger 2003). 
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In a systematic review of the literature, Cooper (2000) found that all reviewed 
studies reported the economic impact of RA to be substantial. The mean 
annual direct costs per person with RA were US $5 720 and indirect costs US 
$5 822. In most studies, costs were not uniformly distributed, with higher costs 
incurred by the patients with the worst RA. The strongest predictor of cost has 
been functional disability (Kavanaugh 2007). 
 
 
2.4.2 Direct costs 
 
Direct costs include the costs of medical care and related items. These 
include expenses for visits to doctors, laboratory and radiological 
examinations, hospital costs, medications, transportation to and from the 
doctors, and special aids (Lubeck 2003). 
 
 
2.4.3 Indirect costs 
 
Indirect costs are those resulting from lost function in one’s usual activity, 
including work disability, sick leave or reduced productivity.  In RA, the indirect 
costs, with the main components of sick leave, part-time work, and early 
retirement, can account for the major part of the general costs, ranging from 
50 to 85% of all costs (Puolakka et al. 2004). 
 
In calculating loss of productivity, the two methods commonly used are the 
human capital and the friction cost approaches. The human capital approach 
values the individual’s productivity at its market price; this is the potential 
gross salary of the individual, including all of the employer’s contributions, and 
for self-employed persons, the gross personal income including statutory 
insurance expenses (Johannesson 1996). The friction cost approach assumes 
that the disabled person is replaced by a currently unemployed person during 
a friction period (Lofland et al. 2001). The friction period is the time during 
which the sick person is replaced, and friction costs include all the expenses 
related to replacing that worker. The human capital approach takes a societal 
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approach, while the friction cost approach includes the costs to the employer 
for replacing the disabled worker.   
 
 
2.4.4 Intangible costs 
 
Intangible costs are defined as pain and suffering of a patient because of 
disease and include reduction in physical function, increased psychological 
distress, and reduced social function. Intangible costs can be measured either 
by the HRQoL questionnaires or alternatively by a contingent valuation 
method that is a stated preference method based on the “elicitation of levels 
of willingness to pay“ (Lubeck 2003, Xie et al. 2008). 
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2.5 Treatment of RA  
 
2.5.1 General 
 
The aim of RA treatment is not only to relieve symptoms and signs, but also to 
prevent destruction of joints. Several studies have shown that lower disease 
activity leads to less radiographic progression (Boers et al. 1997, Makinen et 
al. 2007). The goal of treatment should therefore be to induce remission. Thus 
far, no gold standard of remission criteria in RA patients is available. In clinical 
trials, the American Rheumatism Association (ARA) remission criteria (Pinals 
et al. 1981) or its modifications must serve. Another option is the Disease 
Activity Score with the 28-joint count (DAS28) and a cutpoint of <2.6 as a 
definition of remission in RA (Prevoo et al. 1995), although its use has led to 
criticism (Landewe et al. 2006). 
 
 
2.5.2 Corticosteroids  
 
Corticosteroids have been used for RA treatment since the invention of 
cortisone in the 1940s. Initial enthusiasm for corticosteroids because of their 
dramatic impact on suppressing the inflammation in RA patients ceased when 
their long-term side-effects emerged. Nowadays, the strategy of corticosteroid 
treatment includes three possibilities: step-down with a high initial dose later 
tapered off (Boers et al. 1997), bridge-therapy aimed at controlling symptoms 
in the period of high disease activity before newly started DMARDs start to 
have an effect (van Riel at al. 1999), or a long-term low-dose strategy of oral 
corticosteroids together with a single or a combination of DMARDs (Kirwan 
1995). A recent review has presented ample evidence that low-dose 
corticosteroids together with DMARDs are able to reduce the rate of erosion 
progression in RA patients substantially (Kirwan et al. 2007). On the other 
hand, daily use of corticosteroids has caused the most problems with long-
term toxicity such as cumulative effects on bone that lead to osteoporosis and 
other deleterious effects associated with increased mortality (Wolfe et al. 
1994). 
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2.5.3 Traditional DMARDs   
 
The cornerstone of RA treatment involves DMARDs either as monotherapy or 
in combinations, with or without corticosteroids. Different strategies of RA 
treatment with DMARDs have appeared during the last 20 years. The 
traditional “pyramid” approach included the use of DMARDs only as the last 
option after NSAIDs and corticosteroids had failed. The “sawtooth” strategy 
introduced by Fries (1990) included an earlier start of DMARDs, but these 
were changed sequentially only if the first drug failed (Mottonen et al. 1996, 
Fries et al. 1996). The traditional DMARDs begin to show a clinical effect only 
after 2 to 6 months of treatment. Therefore, those patients who failed the first 
DMARD had long periods without effective treatment before the second 
DMARD began to work (Aletaha and Smolen 2002).  
 
The modern approach of RA treatment includes a very early start of treatment 
because even a delay of 4 months can affect long-term outcome of treatment 
(Lard et al. 2001). In a case-control, parallel-group study among patients who 
started DMARDs after a median disease duration of 3 months (early RA), 60% 
achieved an ACR50 response at 3 years compared with 25% of those who 
started DMARD treatment after a median disease duration of 12 months (late 
RA). In the late-RA group, the radiologic progression rate during a 3-year 
follow-up measured by the Larsen score was significantly higher than in the 
early-RA group (Nell et al. 2004).  
 
During the last decade a strategy of initiating combination treatment with two 
or more DMARDs has become increasingly popular. The aim of combining 
DMARDs with different mechanisms of action is to increase efficacy while 
maintaining a favourable toxicity profile. At least two differing approaches of 
combination treatment exist: the step-down and the step-up strategies. In the 
step-down approach, the most aggressive treatment with combinations of 
DMARDs is used at baseline, and once the disease is under control, the drugs 
with the least favourable toxicity profile are withdrawn. In the step-up 
approach, the DMARDs are added one at a time until the disease is under 
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control, and therefore administration of multiple DMARDs can be avoided in 
patients who respond to a single DMARD. 
 
Several studies of RA patients have compared monotherapy with different 
combinations of DMARDs. Depending on the choice of DMARDs and study 
design, the results have been contradictory. In early RA, the FIN-RACO and 
COBRA studies have shown that combination treatment results in a 
favourable outcome both clinically and radiologically compared to that with 
monotherapy (Mottonen et al. 1999, Boers et al. 1997). In patients with 
established RA, studies have demonstrated that for patients failing with MTX 
or any other single DMARD, combination treatment has been more effective 
than monotherapy (O'Dell et al. 1996 and 2002, Tugwell et al. 1995).  
 
A recent systemic review and metaanalysis that compared MTX monotherapy 
to combination therapy with other non-biologic DMARDs concluded, however, 
that in DMARD-naïve patients the balance of efficacy/toxicity favours MTX 
monotherapy (Katchamart et al. 2008). But this metaanalysis had limitations 
due to the heterogeneity of studies. Many of the studies included a small 
number of patients, most studies used lower doses of MTX than in current 
practice, several used drugs that are not commonly used, and the outcome 
measures were inconsistently reported.  
 
The drug of choice among DMARDS is MTX, which has the highest rate of 
continued long-term therapy. In an analysis by Pincus et al (1992), MTX was 
the only DMARD that was continued in more than 50% of patients for longer 
than 5 years. Among traditional DMARDs, sulphasalazine, 
hydroxychloroquine, leflunomide, cyclosporine and aurothiomalate are also 
still in use.  
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2.5.4 Biologicals 
 
The discovery that the macrophage-derived proinflammatory cytokine TNF-α 
plays a central role in the pathogenesis of RA led to the introduction of TNF-
inhibitors (Brennan et al. 1992). Starting from 1998, the TNF-inhibitors 
infliximab, etanercept, and adalimumab have been approved for the treatment 
of RA. In RCTs, responses to TNF-inhibitors—after failure of initial 
conventional DMARD—have been better than responses to conventional 
DMARD monotherapy (Lipsky et al. 2000, Weinblatt et al. 2003, Bathon et al. 
2000). In early DMARD-naïve RA patients, TNF-inhibitors in combination with 
MTX have shown not only clinical efficacy but also a significantly better 
outcome in radiological progression, when compared to MTX alone 
(Breedveld et al. 2006, St Clair et al. 2004). The safety profile of TNF-
inhibitors in long-term follow-up studies is favourable, with no increase in rates 
of serious adverse events (Weinblatt et al. 2006, Moreland et al. 2006).  
These long-term follow-up studies are, however, still limited to a length of 4 to 
7 years because the TNF-inhibitors have been available only for the last 
decade, and much longer surveillance is necessary to confirm their safety.  
 
In clinical practice, patients who fail to respond to the first TNF-inhibitor 
immediately after the treatment is started, who lose the response later, or who 
suffer an adverse event are often switched to a second TNF-inhibitor. Several 
small observational studies have demonstrated that switching to the second 
TNF-inhibitor can be a good option in the case of treatment failure or an 
adverse event with the first TNF-inhibitor (Buch et al. 2007, Hansen et al. 
2004, Haraoui et al. 2004, van Vollenhoven et al. 2003). Data from a large 
register study showed that RA patients who were switched to a second TNF-
inhibitor had a high continuation rate, with 73% of patients continuing 
treatment after a mean 15 months of follow-up, although among those who 
discontinued treatment, the reasons for stopping the second drug were related 
to the reasons for stopping the first (Hyrich et al. 2007). Drug survival for the 
second TNF-inhibitor after the switch is usually longer than for the first, 
although not as long as for those patients not switched (Hjardem et al. 2007). 
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Other biologicals that are approved for RA treatment are anakinra, an 
interleukin 1 (IL-1) inhibitor; abatacept, a selective co-stimulation modulator; 
and rituximab (RTX), a B-cell-depleting agent that binds specifically to the B-
cell surface antigen CD20. In one RCT, the short-term efficacy and safety of 
anakinra has been favourable (Fleischmann et al. 2003), but in an 
observational study, only 14% of patients continued anakinra after 2 years, 
with most of the discontinuations caused by lack of efficacy (den Broeder et 
al. 2006). RTX in combination with MTX has proven to be more effective than 
placebo plus MTX in patients with RA who had an inadequate response to a 
TNF-inhibitor (Cohen et al. 2006). Another observational study showed RTX 
to be more effective than an alternative TNF-inhibitor after an inadequate 
response to the first TNF-inhibitor (Finckh et al. 2007). A recent study of 
abatacept in RA patients who had failed TNF-inhibitor treatment showed the 
new selective co-stimulation modulator to be clinically efficacious and to have 
an acceptable safety profile (Genovese et al. 2008).  
 
Although the clinical efficacy of new biological compounds has been shown to 
be superior to placebo or MTX in patients with RA, they nevertheless have 
limited efficacy. In fact, only a small proportion of patients achieve 70% 
improvement according to ACR criteria, and remissions are rare. Based on 
RCTs, less than 20% of the ACR criteria is achievable for a number of 
patients (range, 28-58%) (Redlich et al. 2003). Therefore, a number of new 
compounds have been invented, and RCTs to compare new molecules with 
placebo in the treatment of RA are conducted (National Library of Medicine. 
URL: www.ClinicalTrials.gov). 
 
 
2.5.5 Treatment of other inflammatory joint diseases 
 
Both traditional DMARDs and biologicals are available in the treatment of 
other inflammatory joint diseases. In AS, the therapeutic options have long 
been limited to NSAIDs for symptom control and to sulphasalazine in patients 
with predominantly peripheral arthritis. Today the TNF-inhibitors have shown 
excellent clinical efficacy in patients with AS and other SPAs (Braun et al. 
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2005a, 2005b). The Assessment of the SpondyloArthritis International Society 
(ASAS) working group has recommended TNF-inhibitors if the patient has a 
definite AS diagnosis and has active disease for at least 4 weeks based on 
the BATH AS disease activity index (BASDAI). The decision must be based 
on expert opinion, and the AS must be refractory to at least two NSAIDs at full 
doses during 3 months, refractory to treatment with intra-articular steroids (if 
needed), and refractory— in patients with predominantly peripheral arthritis—
to sulphasalazine (Braun et al. 2006). The effect of TNF-inhibitors on HRQoL 
can be even more evident in patients with AS than with RA (Heiberg et al. 
2005). 
 
In JIA, pharmacological treatment depends on subtype and has to run parallel 
to the non-pharmacological options such as physical and occupational 
therapy. Very important is the multidisciplinary team including an 
ophthalmologist, a dentist, a social worker, and a psychologist.  
 
The initial symptomatic therapies in JIA include NSAIDs and intra-articular 
steroids. The more aggressive and earlier use of DMARDs has improved the 
prognosis of JIA during the last 10 years. The first choice among DMARDs in 
persistent and active arthritis is MTX because of its effectiveness and 
acceptable level of side-effects (Ravelli and Martini 2007). Several other 
DMARDs such as hydroxychloroquine, aurathiomalate, sulphasalazine, 
leflunomide, and cyclosporine are still in use. During the last decade, the 
introduction of biologicals has provided a very important option for JIA patients 
who have failed to improve when on conventional treatment with DMARDs. 
 
In acute ReA, NSAIDs serve to suppress inflammation and pain in the joints. 
An acute infection requires antibiotics. Current evidence does not support the 
use of long-term antibiotics for the treatment of acute ReA (Kvien et al. 2004, 
Hannu et al. 2006).  If NSAID treatment fails, then DMARDs can be used. 
Some reports suggest that biologicals can be effective also in chronic cases of 
ReA without reactivating the initiating infection (Brandt et al. 2002, Gill and 
Majithia 2008).   
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3. AIMS OF THE STUDY 
 
 
The purpose of the study was to explore the HRQoL of patients with 
rheumatic diseases with special emphasis on RA patients and to evaluate the 
treatment of inflammatory joint diseases with biologicals in routine practice. 
The specific aims of the study were to examine: 
 
1. the HRQoL of patients with various rheumatic diseases referred to a 
university clinic and to analyse the impact of 8-month routine treatment 
on the HRQoL of those patients. (I) 
 
2. any change in HRQoL during treatment with etanercept and 
adalimumab in patients with RA in routine practice. (II) 
 
3. the one-year costs of patients with chronic inflammatory joint diseases 
during infliximab treatment compared to costs incurred one year before 
infliximab. (III) 
 
4. the clinical impact on RA patients when they switch from infliximab to 
etanercept. (IV) 
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4. PATIENTS AND METHODS 
 
 
The study population comprised patients with various rheumatic diseases 
attending the Department of Rheumatology at Helsinki University Central 
Hospital, except for Study II, where data for patients from Lappeenranta 
Central Hospital were also used. For demographic and clinical characteristics 
of all the patients see Table 2. All patients gave their written informed consent 
to participate, and the local ethics committee approved the study protocols.  
 
In Studies II to IV, TNF-inhibitors were started according to the Finnish 
national recommendations for prescribing biological agents for RA. These 
recommend that the patients should have failed treatment with a combination 
of DMARDs including MTX and a low dose of corticosteroids, and they should 
have active disease, as indicated by the following: more than six swollen 
joints, more than six tender joints, more than 45 minutes of morning stiffness, 
an erythrocyte sedimentation rate (ESR) of at least 30 mm/h or a C-reactive 
protein (CRP) of at least 28 mg/l, or both; and ARA functional class I to III 
(www.kaypahoito.fi/nivelreuma; Finnish current care guidelines for the 
management of rheumatoid arthritis). For other patients with chronic arthritis, 
the same recommendations were modified for clinical practice. The non-
rheumatoid patients are considered eligible to receive biological agents if they 
have chronic peripheral arthritis that fails to respond to a combination of 
DMARDs, including MTX and a low dose of corticosteroids, and have an ESR 
of at least 30 mm/h or a CRP of at least 28 mg/l or both. 
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Table 2.  Demographic and clinical characteristics of the study 
populations 
 Study I Study II Study III Study IV 
N 
Age, years, mean (SD) 
Gender, female (%) 
Duration of disease, 
years, mean (SD) 
RA (%) 
ReA (%) 
Chronic SPAs (%) 
Arthralgia (%) 
OA (%) 
Systemic rheumatic 
diseases (%) 
JIA (%) 
Other (%) 
 
295 
54 (16) 
221 (75) 
6 (10) 
 
99 (33) 
22 (7) 
43 (15) 
47 (16) 
44 (15) 
 
17 (6) 
9 (3) 
14 (5) 
97 
52 (13) 
73 (75) 
17 (10) 
 
97 (100) 
0 
0 
0 
0 
 
0 
0 
0 
96 
48 (12) 
63 (66) 
16 (10) 
 
65 (68) 
8 (8) 
12 (13) 
0 
0 
 
0 
8 (8) 
3 (3) 
 
49 
54 (11) 
43 (88) 
13 (9) 
 
49 (100) 
0 
0 
0 
0 
 
0 
0 
0 
 
SD, standard deviation; RA, rheumatoid arthritis; ReA, reactive arthritis; SPAs, 
spondyloarthropathies; OA, osteoarthritis; JIA, juvenile idiopathic arthritis  
 
 
Study I comprised 295 patients with various rheumatic diseases who had a 
new referral to the Department of Rheumatology of the Helsinki University 
Central Hospital from May 2002 until April 2003. The total number of patients 
receiving the questionnaires was 676, and 385 (57%) of them responded. 
Complete baseline and follow-up data were available for 295 patients. Those 
90 (23%) who responded to the first but not to the follow-up questionnaire can 
be considered dropouts. We compared the available data of the included 
patients to data of excluded patients and found that the excluded patients 
were younger and had less OA and more fibromyalgia and arthralgia, but the 
numbers of RA patients in both groups were similar (Table 3). This study is a 
part of a large ongoing study of secondary health care in the Helsinki 
University Hospital, which started in March 2002 (Räsänen et al. 2005).  
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Table 3.  Characteristics of the included and excluded patients. Modified 
and reprinted with permission from Rheumatology International (Laas et al. 
2009b).   
Characteristics Included patients 
(N=295) 
Excluded patients 
      (N=381) 
Gender, female (%) 222 (75) 265 (70) 
Age, years, mean (SD)          53 (15) 48 (15)* 
RA (%) 99 (34) 121 (32) 
OA (%) 44 (15) 31 (8) 
Arthralgia and fibromyalgia (%) 47 (16) 77 (20) 
Chronic SPAs (%)  
       AS (%) 
       PSA (%) 
       Enteropathic arthritis (%) 
43 (14) 
21 (7)  
          16 (5) 
6 (2)  
67 (18) 
38 (10) 
          25 (7)  
          4 (1) 
JIA (%) 
ReA (%) 
Systemic rheumatic diseases 
(%) 
Other (%) 
9 (3) 
           22 (7) 
 17 (6)  
  
14 (5) 
11 (3) 
           19 (5)  
           17 (5)  
 
32 (8) 
* Statistically significant difference (p<0.001) 
Abbreviations as in Table 2. 
 
 
For analyses of HRQoL, the patients were divided into eight groups according 
to diagnosis: 99 RA, 44 OA, 47 arthralgia and fibromyalgia, 43 chronic SPAs 
(AS, PSA, enteropathic arthritis), 22 ReA, 17 systemic rheumatic diseases, 9 
JIA, and 14 other.  
 
 36 
To analyse in RA patients whether HRQoL was related to duration of disease, 
we made two groups according to disease duration: 47 patients with RA for 2 
years or less as the early-RA group and 52 patients with RA over 2 years as 
the late-RA group.  
 
For comparing the HRQoL of our study population with that of the general 
population, we used the general Finnish population data on HRQoL, as 
measured by the 15D, from the health examination survey “Health 2000” 
(Aromaa and Koskinen 2004). 
 
Study II   
In the second study, 97 RA patients who started treatment with adalimumab 
or etanercept at Helsinki University Central Hospital or at Lappeenranta 
Central Hospital during 2003-2006 were asked to participate. The choice of 
TNF-inhibitor was made on clinical grounds by the rheumatologist treating 
each patient. Adalimumab was given 40 mg subcutaneously every other week 
and etanercept 25 mg subcutaneously twice weekly. Patients were seen by 
the rheumatologist at baseline and 3 months after the first visit. 
 
Study III comprised 96 patients with different arthritis diagnoses. Besides 65 
patients with RA, 8 patients had chronic ReA, 8 JIA, 6 PSA, 6 AS, 2 adult-
onset Still’s disease, and one had SAPHO (Synovitis-Acne-Pustulosis-
Hyperostosis-Osteomyelitis) syndrome. All patients were using DMARDs, 
61% as monotherapy and 39% in various combinations. The majority (82%) 
were using corticosteroids. MTX was the most common DMARD either as 
monotherapy or in combinations.  
 
Treatment with infliximab was started at a dosage of 3 mg/kg, which was 
rounded off to the nearest 100 mg and was administered at weeks 0, 2, 6, and 
every 8 weeks thereafter. If the response was insufficient, the dose or the 
interval could be adjusted. 
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Study IV  
In the fourth study, 49 patients with RA who were switched from infliximab to 
etanercept during 1999-2003 were recruited. Infliximab was discontinued 
because of failure to respond in 20 (42%) patients, adverse events in 6 (12%), 
and non-medical reasons in 23 (46%). We used the term “non-medical 
reasons” for patients who were switched to etanercept for their own 
convenience or to avoid visiting the hospital for infliximab infusions. Infliximab 
was used as described in Study III and etanercept as in Study II. 
 
 
Follow-up and outcome analyses 
 
Clinical evaluation 
In Study I, clinical data, including ESR, CRP, use of DMARDs and oral 
corticosteroids, and interventions and consultations by health professionals, 
were gathered retrospectively from patient records. In Studies II to IV, a 
thorough clinical evaluation was conducted on the first visit. Disease activity 
was measured by tender-joint count (of 68), swollen-joint count (of 66), by 
patient’s and physician’s global assessment of disease activity on a visual 
analogue scale (VAS) ranging from 0 (no symptoms) to 10 (most severe 
disease), by patient’s assessment of pain on VAS from 0 to 10, and by ESR 
and CRP. In addition, demographic data included age, gender, disease 
duration, presence or absence of RF, and current use of DMARDs and 
corticosteroids. In all studies, functional status was evaluated with the Finnish 
version of the HAQ (Hakala et al. 1994). The disability index was calculated 
on a scale of 0 to 3, based on answers to the questionnaire. 
 
In Study IV, DAS28 was used to compare clinical outcome with infliximab and 
etanercept. The individual patients’ DAS28 was calculated at baseline, at 3, 6, 
and 9 months, and at the last visit, based on data for 28 swollen and tender 
joints. The clinical benefit of etanercept as a second biological was compared 
between the three groups depending on reason for infliximab discontinuation.  
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HRQoL 
In the first study, 15D was used to measure HRQoL. Patients filled in the 15D 
and HAQ questionnaires on average 28 (SD19) days before the first visit. 
After 8 months, all patients were sent the questionnaires again which they 
filled in on average 236 (SD28) days after the first visit. 
 
In Study II, the RAND-36 was used to measure the HRQoL (Hays et al. 1993, 
Aalto et al. 1999). The patients filled in the questionnaires of the RAND-36 
and HAQ at baseline and 3 months after the first visit.  
 
 
Costs 
 
In Study III, economic data came from case records for the year preceding the 
start of infliximab treatment (period I) and for the subsequent first infliximab 
treatment year (period II) also including data from patients discontinuing 
infliximab before a year had elapsed from start of treatment.  
 
Medical costs  
Medical costs included costs of visits to the outpatient clinic or day unit, and 
costs of inpatient stays and orthopaedic operations. We also calculated the 
costs of DMARDs and corticosteroids but omitted the costs of NSAIDs and 
other painkillers and drugs for nonrheumatic diseases, because information 
on the use of these drugs was often lacking from medical records. Nor was 
information on primary health care costs available. Because costs for aid 
appliances, transportation, rehabilitation, and assistive devices were 
excluded, we used the term “medical costs” instead of “direct costs”, referring 
to the most relevant medication costs. 
 
Work disability costs 
For estimation of lost productivity, the human capital approach (Johannesson 
1996) was chosen. A person’s productivity was defined as the total costs to an 
employer including salary along with any supplementary social welfare 
expenses. In the case of self-employment, productivity was defined as 
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personal income plus any statutory health and pension insurance expenses. 
To calculate the work disability costs, we recorded patient’s occupation, 
employment status, and number of days off work from case records, which 
included certificates documenting the patient’s work incapacity for claims for a 
sickness or rehabilitation allowance or a disability pension. The rehabilitation 
allowance is a cash benefit for persons who go through medical or surgical 
interventions or for those who take part in a rehabilitation program to restore 
work ability and thus have to be absent from their regular work for at least one 
year.  Information on median wages by occupation in 2002 came from the 
Official Statistics Finland (http://www.stat.fi/til/pal_en.html). Because wages 
have increased approximately 3% per year, we calculated the income of the 
year for which patient data were collected. The supplementary social welfare 
expenses (32.2% of income) were added to yield the monetary value of work 
productivity. The cost of lost productivity was calculated per day.  
 
The number of sickness absence days was calculated for each full- or half-
time working patient and multiplied by earnings per day. We use the term 
“work disability costs” instead of “indirect costs” because not all indirect costs 
were calculated. In 39 patients who had retired before study entry we included 
only medical costs in the analyses because during the study period the 
disability costs remained unchanged.  
 
Unit costs 
Unit costs of outpatient and day-unit visits came from the Helsinki University 
Central Hospital Catalogue for 2002, and the total costs of hospitalisations 
(including laboratory and radiological examinations, operations and drugs) of 
every patient came from the financial department of Helsinki University 
Central Hospital or from local hospitals. The Finnish Pharmacotherapy 
Catalogue 2002 provided drug prices. The price of infliximab is included in the 
cost of a day-unit visit for a patient receiving infliximab or in the cost of a visit 
to a rheumatology ward in Helsinki. The costs of laboratory tests and 
investigations were included in the price of a visit in the outpatient clinic. In 
euros, the 2002 price of infliximab per 100 mg was €538.37. The cost of one 
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outpatient visit was €106. The usual cost of a day-unit visit was €436 and for 
an infliximab patient €1 430.  
 
 
 Statistical methods 
 
The results are given as means and standard deviations (SD) for normally 
distributed continuous variables, medians and ranges, or as lower and upper 
quartiles and 95% confidence intervals (CI) for continuous variables with 
skewed distributions, and as percentages for categorical variables. For 
continuous variables, the significance of the differences between the groups 
was analysed by the independent samples t-test or the Mann-Whitney test. In 
Studies III and IV, analyses of clinical outcome were performed according to 
the last-observation-carried-forward method. 
 
In Study I, the significance of the differences between before and after 
treatment scores was analysed with the Student's paired samples t-test or the 
Wilcoxon test. Correlation of the HRQoL change with that observed in the 
HAQ scores and with the ESR and CRP values was studied with Spearman 
correlation. The significance of differences in categorical variables between 
groups was analysed with the Chi-square or Fisher’s Exact Test. 
 
In Study II, the between-group differences in change in the RAND-36 domains 
over the 3-month treatment period were compared by a bootstrap-type 
ANCOVA with the baseline measurement as a covariate and by a multivariate 
Hotelling-type permutation test. Changes within groups were analysed by 
applying a permutation test or a Hotelling-type permutation test to related 
samples.  The effect size ("d") was calculated by the method for paired 
samples: mean baseline scores minus mean follow-up scores, divided by the 
pooled standard deviation; 95% CI were obtained by bias-corrected 
bootstrapping (5000 replications). The Finnish general population values for 
the eight RAND-36 domains were weighted to match the gender- and age 
distribution of the study population. 
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In Study III, the CIs for the means were obtained by bias-corrected 
bootstrapping (10 000 replications) because the cost data were skewed (Efron 
and Tibshirani 1993). Statistical comparison of changes in outcome 
measurements was performed by the Wilcoxon signed ranks test (Monte 
Carlo p-value) and Hodges-Lehmann estimation of median difference. 
 
In Study IV, the statistical significance between groups was evaluated by 
permutation-type tests (Monte Carlo p-value) or the Fisher-Freeman-Halton 
test. Statistical comparison of changes in DAS28 measurement was 
performed by permutation-type tests. Time-to-event analysis based on the 
product limit estimate (bootstrap estimation) was used to derive a 95% CI of 
the cumulative “drug survival” function. A log-rank test with exact p-values 
identified statistical differences between cumulative proportions. 
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5. RESULTS 
 
 
5.1. HRQoL in patients with common rheumatic diseases referred to a 
university clinic (I) 
 
The baseline clinical characteristics of the patients in different disease groups 
are in Table 4. The mean (SD) 15D score of all rheumatic patients improved 
significantly (p<0.001) from 0.822 (0.114) at baseline to 0.840 (0.119) at the 
8-month follow-up. Both the baseline and the follow-up 15D scores were 
significantly lower than the HRQoL of the age-standardized general population 
(p<0.05). Of the 15 dimensions covered by 15D, significant differences 
between patients and the general population were found in 11 dimensions, 
and the largest difference was for the dimension of discomfort and symptoms 
(Fig. 1). 
 
Discomfort and symptoms, a dimension of 15D, was the one most affected 
dimension in patients with rheumatic diseases. We therefore present the data 
of this dimension in Table 5 together with the HRQoL and HAQ results. The 
lowest baseline HRQoL was in patients with OA and chronic SPAs. In patients 
with RA and ReA the improvement in the HRQoL during the 8-month follow-up 
was statistically significant. A clinically important change was reported by 
patients with ReA and systemic rheumatic diseases but not by the RA 
patients. The poorest HAQ score both at baseline and also at follow-up was in 
patients with RA. The HAQ score improved significantly in patients with RA, 
arthralgia and fibromyalgia, and ReA. 
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Figure 1.  15D profiles of patients with common rheumatic dieseases 
(n=295) at baseline and at 8-month follow-up compared to an age-
standardized general population. (* denotes significant improvement from 
baseline at the p<0.05 level, and *** at the 0.001 level). The mean values are 
used.  Modified and reprinted with permission from Rheumatology 
International (Laas et al. 2009b). 
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Table 5.  Mean (SD) HRQoL (15D), discomfort and symptoms, and disability 
index of patients among diagnostic groups. Modified and reprinted with permission 
from Rheumatology International (Laas et al. 2009b). 
Disease 
group 
 
HRQoL 
(SD) at 
baseline 
HRQoL 
(SD) at 8 
months 
Disco 
(SD) at 
baseline 
 
Disco (SD) 
at 8 months 
 
HAQ 
(SD) at 
baseline 
HAQ (SD) 
at 8 
months 
RA (n=99) 
 
0.815 
(0.115) 
0.840 
(0.122)** 
0.529 
(0.228) 
0.634 
(0.218)*** 
 
0.843 
(0.639) 
0.623 
(0.675)** 
OA (n=44) 0.810 
(0.103) 
0.813 
(0.114) 
0.546 
(0.181) 
0.567 
(0.213) 
0.561 
(0.518) 
0.564 
(0.529) 
Arthralgia 
and 
fibromyalgia 
(n=47) 
 
0.835 
(0.094) 
0.841 
(0.113) 
0.492 
(0.182) 
0.607 
(0.238)*** 
0.474 
(0.444) 
0.360 
(0.468)** 
Chronic 
SPAs 
(n=43) 
0.810 
(0.133) 
0.825 
(0.137) 
0.494 
(0.247) 
0.626 
(0.249)** 
0.457 
(0.443) 
0.383 
(0.497) 
ReA 
(n=22) 
0.849 
(0.112) 
0.902 
(0.083)** 
0.518 
(0.229) 
0.720 
(0.180)** 
0.566 
(0.655) 
0.235 
(0.448)* 
Systemic 
rheumatic 
diseases 
(n=17) 
 
0.843 
(0.099) 
0.880 
(0.088) 
0.582 
(0.201) 
0.700 
(0.184)* 
0.712 
(0.565) 
0.387 
(0.476) 
JIA  
(n=9) 
0.928 
(0.058) 
0.927 
(0.066) 
0.801 
(0.148) 
0.900 
(0.148) 
0.232 
(0.561) 
0.196 
(0.352) 
Other (n=14) 0.787 
(0.153) 
0.770 
(0.126) 
0.533 
(0.220) 
0.557 
(0.179) 
0.510 
(0.542) 
0.614 
(0.706) 
HRQoL, health-related quality of life; SD, standard deviation; Disco, discomfort and 
symptoms; HAQ, Health Assessment Questionnaire. Other abbreviations as in  
Table 4. Changes statistically significant * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Besides visits to the rheumatologist, 127 (43%) patients also received 
treatment from or had a consultation with at least one member of the 
multidisciplinary team. Total number of visits and treatments was 244. Among 
the patient groups, 58% of patients with chronic SPAs, 55% with RA, and 46% 
with OA received multidisciplinary care. Of RA patients, 62% with early RA 
and 48% with late RA received multidisciplinary care. The provider of 
multidisciplinary care most frequently visited was the physiotherapist (Table 
6). 
 
 
Table 6.  Multidisciplinary care in all rheumatic (n=295) and rheumatoid arthritis 
(RA) patients (n=99).  
Type of multidisciplinary care All patients  
number (%) 
RA patients  
number (%) 
 
Physiotherapist  77 (26) 34 (34) 
Appliances  40 (14) 25 (25) 
Occupational therapy  28 (10) 19 (19) 
Social worker  18 (6) 12 (12) 
Podotherapy  3 (1) 3 (3) 
Rehabilitation program 
consultation  
17 (6) 13 (13) 
Rehabilitation at health center  34 (12) 6 (6) 
Rehabilitation in inpatient 
facilities  
2 (1) 1 (1) 
Orthopedic surgeon 
consultation  
18 (6) 11 (11) 
Joint surgery  7 (2) 3 (3) 
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5.1.1 The HRQoL of patients with RA 
 
Patients with RA had at baseline a significantly worse HRQoL than did the 
general population on the following dimensions: moving, breathing, sleeping, 
usual activities, discomfort and symptoms, depression, distress, and vitality 
(Figure 2). In 47 patients with early RA, the mean (SD) HRQoL improved 
during 8 months significantly from 0.813 (0.115) to 0.844 (0.141), p<0.05. This 
kind of improvement was not observed in 52 patients with late RA. 
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Figure 2. 15D profiles of RA patients (n=99) at baseline and at 8-month 
follow-up compared to an age-standardized general population.  (* denotes 
significant improvement from baseline at the p<0.05 level, and *** at the 0.001 
level). The mean values are used.  Modified and reprinted with permission 
from Rheumatology International (Laas et al. 2009b). 
 
At baseline, 34 (34%) patients with RA received treatment with DMARDs. 
Treatment with DMARDs or corticosteroids was started at the first visit in 58 
DMARD-naïve RA patients. Only seven patients with RA were without any 
DMARD or corticosteroid treatment at follow-up (Table 7). In one patient, anti-
TNF treatment was started in addition to DMARDs.  
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Table 7.     DMARD and corticosteroid treatment of RA patients (n=99) at follow-up. 
Variable Number of patients % 
Drugs:   
      Methotrexate 53 53 
      Hydroxychloroquine 35 35 
      Sulphasalazine 33 33 
      Gold salts, i.m. or p.o. 5 5 
      Podophyllotoxin 1 1 
      Leflunomide 1 1 
     Corticosteroids 30 30 
Treatment strategy:   
     Single DMARD therapy 36 
 
37 
 
  Single DMARD therapy with     
corticosteroids          
21 
 
21 
 
     Combination DMARD therapy  6 
 
6 
 
     Combination DMARD therapy with   
corticosteroids 
 
25 
 
25 
     Corticosteroids without DMARD  therapy  4 
 
4 
 
      No therapy 7 7 
 
DMARDs, disease-modifying anti-rheumatic drugs; i.m., intra-muscular; p.o., per oral 
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5.2 Biologicals etanercept and adalimumab already improve HRQoL 
in patients with RA after 3 months of treatment (II) 
 
In 97 patients with RA, the first biological treatment was started: in 58 patients 
with etanercept and in 39 with adalimumab. At baseline, 90 (93%) patients 
were using DMARDs with or without corticosteroids (Table 8). The clinical and 
demographic variables of the two study groups in the beginning of the study 
were comparable (Table 9).  
 
The improvement in eight domains of the RAND-36 after 3 months of 
treatment was statistically significant both with etanercept (p=0.041) and with 
adalimumab (p=0.019) (Table 10). The two biologicals did not differ from each 
other regarding improvement in HRQoL (p=0.30). Both groups reported 
significant changes in the dimension of bodily pain. The etanercept group 
reported additionally a significant improvement in physical functioning, energy, 
social functioning, role functioning/emotional, and emotional well-being, but 
the adalimumab group only in general health. 
 
The median (IQR) decrease in the HAQ in the etanercept group was 0.25 
(0.12 ; 0.5) and in the adalimumab group 0.25 (0.13 ; 0.6), both of these 
changes were clinically important but only in the etanercept group did the 
improvement reach statistical significance. After 3 months of treatment, 
patients in both groups experienced clinically important and statistically 
significant improvements in all clinical variables (Table 11). 
 
The largest differences in HRQoL between RA patients and the age- and 
gender-matched general population were in the physical domains of the 
RAND-36 both at baseline and after 3 months of treatment (Figure 3). 
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Table 8.         DMARD and corticosteroid use at baseline with no statistically 
significant difference between groups. Modified and reprinted with permission 
from Clinical and Experimental Rheumatology (Laas et al. 2009a).  
Variable Etanercept  
n=58  
(%) 
Adalimumab  
n=39 
(%) 
All 
N=97 
Drugs: 
 
   
Methotrexate 31 (53) 22 (56) 53 (55) 
Hydroxychloroquine 18 (31) 11 (29) 29 (30) 
Sulphasalazine 17 (29) 9 (23) 26 (27) 
Podophyllotoxin  13 (22) 9 (24) 22 (23) 
Leflunomide  11 (19) 11 (28) 22 (23) 
Cyclosporine 10 (17) 6 (16) 16 (17) 
Gold salts, i.m. or p.o. 4 (7) 3 (8) 7 (7) 
Azathioprine 2 (3) 1 (3) 3 (3) 
Corticosteroids 52 (76) 33 (75) 85 (76) 
Treatment strategy:    
No drugs 1 (2) 0 1 (1) 
Single DMARD 6 (10) 6 (15) 12 (12 
Single DMARD with corticosteroids 10 (17) 10 (26) 20 (21) 
Corticosteroids alone 6 (10) 2 (5) 8 (8) 
Combination of DMARDs 7 (12) 2 (5) 9 (9) 
Combination of DMARDs with corticosteroids 28 (48) 19 (49) 47 (48) 
DMARDs, disease-modifying anti-rheumatic drugs; i.m., intra-muscular; p.o., 
per oral 
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Table 9.       Baseline demographic and clinical characteristics of patients treated 
with etanercept or adalimumab with mean values (SD) or number of patients 
(percentages). Modified and reprinted with permission from Clinical and Experimental 
Rheumatology (Laas et al. 2009a).  
Variable  Etanercept 
n=58 
Adalimumab 
n=39 
All 
n=97 
Female (%) 
Age, yrs (SD) 
Duration of RA, years (range) 
Seropositivity (%) 
Number of tender joints, 0-68 (SD) 
Number of swollen joints, 0-66 (SD) 
Pain, VAS cm (SD) 
Patient global assessment, VAS cm 
(SD) 
Physician global, VAS cm (SD) 
ESR, mm/h (SD) 
CRP, mg/l (SD) 
HAQ (SD) 
74 
50 (14) 
16 (1-47) 
79 
7 (5) 
11 (10) 
6 (2) 
6 (2) 
 
5 (2) 
43 (25) 
34 (5) 
1.22 (0.68) 
76 
55 (11) 
17 (1-37) 
67 
10 (7) 
12 (10) 
6 (3) 
6 (2) 
 
4 (2) 
38 (23) 
29 (7) 
1.14 (0.72) 
75 
52 (13) 
17 (1-47) 
74 
9 (6) 
11 (10) 
6 (2) 
6 (2) 
 
4 (2) 
40 (24) 
31 (24) 
1.18 (0.7) 
SD, standard deviation; ESR, erythrocyte sedimentation rate; CRP, C-reactive 
protein; RA, rheumatoid arthritis; VAS, visual analogue scale; HAQ, health 
assessment questionnaire 
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Figure 3      RAND-36 domains of treatment groups at baseline and at 3 
months compared to an age- and gender-matched general population ( ---). 
Modified and reprinted with permission from Clinical and Experimental 
Rheumatology (Laas et al. 2009a).  
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5.3 Clinical outcome and costs of treating chronic arthritis patients 
with infliximab for one year (III) 
 
5.3.1 Clinical outcome 
 
In 96 patients with different types of chronic arthritis who had failed to improve 
with combinations of DMARDs including MTX and corticosteroids, infliximab 
was started. Baseline demographic characteristics in different disease groups 
appear in Table 12. The improvement in all clinical variables during one year 
of infliximab treatment was statistically significant compared to baseline (Table 
13). The median (IQR) improvement in HAQ score was 0.56 (0.81; 0.25), and 
this is also clinically significant. A total of 22 patients discontinued infliximab 
before one year, 14 because of failure to respond by > ACR 50%, 4 because 
of adverse events, and 4 for other reasons. The adverse events were allergic 
reactions in three patients and lupus-like dermatitis in one patient. 
 
 
Table 12.    Baseline demographic characteristics of patients among disease groups, 
with means (SD) or percentages. 
Variables RA 
n=65 
ReA 
n=8 
JIA  
n=8  
SPA 
n=6 
PSA 
n=6 
Still  
n=2  
Sapho 
n=1 
Age, yrs (SD) 51 (11) 43 (9) 34 (7) 48 (14) 43 (10) 27 (5) 51 (0) 
Number of 
female, %  
77 38  63 33 17 50 100 
Disease 
duration, yrs 
(SD) 
14 (9) 15 (6) 26 (12) 22 (12) 12 (6) 14 (15) 3 (0) 
Retired 
patients, % 
48 50 63 50 17 0 100 
Discontinuing 
patients, % 
26 38 0 17 0 50 0 
RA, rheumatoid arthritis; ReA, reactive arthritis; JIA, juvenile idiopathic arthritis; SPA, 
spondyloarthropathy; PSA, psoriatic arthritis; SD, standard deviation 
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Table 13.          Change in clinical variables during the second study year (period II) 
for all 96 patients. By analysis based on intention to treat by a last-observation 
carried-forward method, the statistical significance for each comparison was at the 
p<0.001 level. Modified and reprinted with permission from Annals of the Rheumatic 
Diseases (Laas et al. 2006).  
Variables 
 
Baseline 
Median (IQR) 
Change to months 12 
Median (95% CI) † 
Number of swollen joints 13 (7; 20) -9 (-11 to -7) 
Number of tender joints 18 (10; 25) -12 (-15 to -10) 
Pain (VAS, cm) 7 (5; 8) -3 (-4 to -2 ) 
Patients global assessment (VAS, 
cm) 
7 (6; 8) -4 (-5 to -3) 
Physicians global assessment 
(VAS, cm) 
7 (5; 8) -4 (-5 to -3) 
HAQ 1.37 (1.00; 2.12)  -0.56 (-0.81 to -0.25) 
ESR, mm/h    51 (31; 76) -24 (-32 to -16) 
CRP, mg/l 49 (22; 76) -29 (-41 to -18) 
 † Hodges-Lehmann estimates of median difference 
IQR, interquartile range; VAS, visual analogue scale; HAQ, Stanford Health 
Assessment Questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive 
protein 
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5.3.2 Costs 
 
During period II, the number of day-ward and rheumatology department visits 
increased, and the number of out-patient visits decreased (Table 14). The 
number of admissions to other wards and orthopaedic operations during both 
periods were comparable.  
 
 
Table 14.  Number of visits per patient (n=96) during one year prior to (period I) and 
during one year after institution of infliximab (period II). 
 Period I  Period II  
 Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median 
(IQR) 
Number of outpatient    
visits 
 
4.6 (2.8) 4 (3;  6) 0.3 (1.2) 0  
Number of hospital 
admissions to 
rheumatology ward 
 
0.6 (0.9) 0 (0; 1) 1.5 (2.4) 0 (0; 2) 
Number of day-ward 
visits 
 
2.3 (1.9) 1 (1; 4) 8.3 (1.8) 8 (8; 10) 
Number of hospital 
admissions to other 
wards 
 
0.4 (0.2) 0 0.1 (0.3) 0 
Number of orthopaedic 
operations 
0.2 (0.5) 0 0.3 (0.5) 0 
SD, standard deviation; IQR, interquartile range 
 
 
Medical costs increased during period II by €12 015 (95% CI, 6 496 to 18 076) 
per patient compared to period I. The costs rose due to visits for infliximab 
infusions either in the day-ward or in the rheumatology department (Table 15). 
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The mean drug cost of one-year treatment with infliximab was €9 080. Thus, 
the price of infliximab accounted for 75% of the increase in medical costs. 
During period II, a slight decrease occurred in the costs of outpatient visits, 
conventional DMARDs, and corticosteroids. Those 22 patients who 
discontinued infliximab prior to one year were responsible for 58% of hospital 
admission costs not related to infliximab administration in period II. After 
infliximab discontinuation, those patients needed hospitalisation either for 
treatment of adverse events or because of RA severity. The total costs for 
patients with RA were higher than for patients with non-RA during both 
periods, but the difference in costs was not statistically significant (Table 16).  
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Table 16.       Total costs per patient during one year prior to (period I) and one year 
after initiation of infliximab (period II) in patients with RA and in patients with other 
diagnoses (Non-RA). Median values (IQR). 
Costs, € RA patients,  
n=65 
Non-RA patients, n=31 All patients,  
n=96 
Period I 5 644 (2 766, 13 469) 4 933 (2 625, 18 175) 5 418 (2 721, 13 489 ) 
Period II 14 187 (12 183,  
23 945) 
14 018 (11 771,  
22 798) 
14 102 (11 933,  
22 996) 
RA, rheumatoid arthritis; IQR, interquartile range 
 
 
At the start of infliximab infusions, 49% of patients were working full-time and 
4% half-time; 41% were retired because of work disability, and 6% were 
retired as being over 63. Mean work disability costs for those 51 patients 
available for the active work force decreased by €130 (95% CI : -1 268 to 1 
072) during period II. At the same time, the mean number of days off work on 
short-term sick-leave or rehabilitation allowance increased from 121 during 
period I to 141 during period II. In addition, 11 patients during period I and 12 
patients during period II were on a rehabilitation allowance. 
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5.4 Clinical impact of switching from infliximab to etanercept in 
patients with RA (IV) 
 
 
5.4.1 Baseline characteristics of patients 
 
Altogether 49 patients with RA were switched from infliximab to etanercept 
treatment, and they were divided into three groups according to the reason for 
the switch: 20 patients because of infliximab failure, 6 because of an adverse 
event, and 23 for some non-medical reason.  
 
At baseline, clinical characteristics of patients in the groups did not differ from 
each other with only the exception of infliximab-treatment duration (Table 17). 
All patients were using DMARDs, and 88% used corticosteroids. MTX was the 
most common DMARD either as monotherapy or in combinations (Table 18). 
Drug survival for infliximab differed between the groups infliximab failure, 
adverse event, and non-medical reason (Figure 4). 
 
 
5.4.2 Safety of switching from infliximab to etanercept 
 
Etanercept was discontinued in 20 cases: for lack of efficacy in 12 cases and 
adverse events in 7. One patient died, the cause of death being complications 
after hip fracture. The adverse events included: allergic reactions in three, 
infections in two, demyelinating neuropathy in one, and subjective symptoms 
(subfebrile fever, head ache) in one patient. No patient developed 
tuberculosis, a possible TNF-inhibitor associated infection. One patient with 
an allergic skin rash during infliximab had a similar rash after 4 months of 
etanercept and thus had to discontinue the treatment. The mean (SD) time to 
discontinuation of etanercept was 4 (2) months (Figure 5). 
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Table 17.    Baseline clinical characteristics of 49 patients grouped according to 
reasons for switching from infliximab to etanercept. Reprinted and modified with 
permission from Clinical Rheumatology (Laas et al. 2008). 
Characteristics Infliximab 
failure 
(N=20) 
Adverse 
event 
(N=6) 
Non-medical 
reason 
(N=23) 
p-value 
Number of female (%) 15 (75) 6 (100) 22 (96) 0.09 
Age, years, mean (SD) 51 (12) 56 (11) 50 (10) 0.51 
Seropositivity (%) 13 (65) 5 (83) 14 (61) 0.77 
Duration of disease, years, 
median, (range) 
8 (1-32) 12 (5-26) 16 (3-38) 0.06 
Duration of infliximab, 
months, median (range) 
16 (1-32) 6 (1-32) 27 (10-44) <0.001 
Number of previous 
DMARDs, median (range) 
6 (3-10) 7 (5-8) 7 (3-8) 0.95 
SD, standard deviation; DMARD, disease-modifying anti-rheumatic drug 
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Table 18.     Use of DMARDs and corticosteroids at the introduction of infliximab 
Therapy Infliximab failure 
N (%) 
Adverse event 
N (%) 
Non-medical 
reason 
N (%) 
Drugs    
   Methotrexate 12 (60) 3 (50) 17 (74) 
   Gold salts, i.m. or p.o. 2 (10) 0 2 (8) 
   Hydroxychloroquine 2 (10) 1 (17) 4 (17) 
   Azathioprine 1 (5) 0 3 (13) 
   Leflunomide 7 (35) 1 (17) 2 (9) 
   Sulphasalazine  3 (15) 0 1 (4) 
   Cyclosporine 1 (5) 2 (33) 3 (13) 
   Podophyllotoxin 1 (5) 2 (33) 5 (22) 
   Corticosteroids 19 (95) 5 (83) 19 (83) 
Strategy    
   Single therapy 1 (5) 1 (17) 2 (9) 
   Single therapy with corticosteroids 13 (65) 2 (33) 11 (48) 
   Combination therapy 0 0 2 (9) 
   Combination therapy with 
corticosteroids  
6 (30) 3 (50) 8 (34) 
DMARD, disease-modifying anti-rheumatic drug; i.m., intra-muscular; p.o., per oral 
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Figure 4.    Drug survival for infliximab in groups according to reasons for switching 
from infliximab to etanercept. Reprinted with permission from Clinical Rheumatology 
(Laas et al. 2008).  
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Figure 5.    Drug survival for etanercept in groups according to reasons for switching 
from infliximab to etanercept. Reprinted with permission from Clinical Rheumatology 
(Laas et al. 2008).  
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5.4.3 Clinical outcome of switching from infliximab to etanercept 
 
In the non-medical-reasons group, the mean (SD) DAS28 before switching 
from infliximab to etanercept treatment was 2.61 (0.9); this increased slightly 
after switching, by 0.38 (95% CI, -0.12 to 0.95), statistically not significantly 
(p=0.136). The mean (SD) DAS28 before switching in the infliximab failure 
group was 5.49 (1.4) and in the adverse event group 5.06 (1.4). After 
switching, a statistically significant decrease in the DAS28 appeared in both 
groups: -1.19 (95% CI, -2.14 to –0.31, p=0.023) in the infliximab failure group; 
and -1.30 (95% CI, -2.32 to –0.32, p=0.048) in the adverse event group 
(Figure 6). 
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Figure 6.    Clinical outcome during infliximab and etanercept treatment based 
on DAS28 in groups according to reasons for switching from infliximab to 
etanercept. Proposed remission cut-off point of DAS28 at 2.6 (---). Reprinted 
and modified with permission from Clinical Rheumatology (Laas et al. 2008). 
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6.  DISCUSSION 
 
 
6.1 HRQoL in patients with common rheumatic diseases  
 
The 295 patients referred to the rheumatology clinic had a significantly lower 
baseline HRQoL than did the age-standardized general population. Analyses 
of HRQoL among disease groups revealed that the poorest HRQoL was in 
patients with OA and SPA and the poorest HAQ disability index ratings in 
patients with RA. Treatment adjustments improved statistically significantly the 
HRQoL of patients with RA and ReA, and an improvement in HAQ was 
observable in patients with RA, arthralgia and fibromyalgia, and ReA. A 
clinically important change of more than 0.03 units in 15D was reported by 
patients with ReA and systemic rheumatic diseases but not by those with RA. 
The dimension of the 15D most affected, discomfort and symptoms, improved 
in all patients except in those with OA and JIA.  
 
In our study, only one patient with RA received anti-TNF treatment, whereas 
most of the patients had a single or a combination of DMARDs. Improvement 
of HRQoL may be even greater with the use of anti-TNF treatments (Kimel et 
al. 2008, van der Heijde et al. 2005). 
 
Patients with musculoskeletal disorders have had a poorer HRQoL than those 
with other chronic diseases (Sprangers et al. 2000, Alonso et al. 2004, Loza et 
al. 2008). Poor HRQoL is associated with the dimensions of pain and physical 
functioning (Reginster 2002). One population-based cohort study showed that 
patients with OA of the hip or knee, RA, osteoporosis, or fibromyalgia reported 
the worst HRQoL (Picavet and Hoeymans 2004). Our results are in line with 
those findings. 
 
Patients with RA had a significantly lower HRQoL at baseline and at follow-up 
than did the age-adjusted general population. The dimensions of 15D most 
affected were those associated with physical functioning: moving, usual 
activities, discomfort and symptoms, but also those associated with mental 
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functioning: sleeping, depression, distress, and vitality. These findings are in 
accordance with earlier ones in regard to HRQoL in patients with RA (Uhlig et 
al. 2007, Chorus et al. 2003). In our study, patients with early RA experienced 
statistically significant improvement in their HRQoL, whereas those with late 
RA failed to improve significantly. Similarly, studies of early arthritis have 
shown that treatment can restore the HRQoL when started in the early 
disease phase. In a registry study from northern Sweden, the HRQoL of 
patients with recent-onset RA (< 1 year) improved both statistically and 
clinically significantly during a 24-month follow-up (West and Jonsson 2005). 
In a RCT of early RA patients (< 3 years) treated either with etanercept or 
MTX, the 52-week improvement in HRQoL for both treatment groups was 
statistically significant (Kosinski et al. 2002).  
 
The HRQoL of patients in the chronic SPA group was one of the poorest and 
failed to improve during 8 months of follow-up. Earlier studies showed that 
patients with psoriatic arthritis and ankylosing spondylitis have a lower HRQoL 
than does the general population, one that can be as low as the HRQoL in RA 
patients (Husted et al. 2001, Zink et al. 2006). Several RCTs of anti-TNF 
treatments in AS patients focusing on HRQoL have shown a good clinical 
response and a statistically significant improvement (Han et al. 2007, Davis et 
al. 2005).   
 
Patients with ReA reported in our study significant improvement both in their 
HAQ level and their HRQoL that can be explained – besides as good 
treatment effect – also by the natural course of the disease. ReA can resolve 
spontaneously during 3 to 12 months or progress to chronic disease. Only 15 
to 20% of patients develop chronic disabling symptoms (Wu & Schwartz 
2008). 
 
Our patients with OA had a short median (IQR) disease duration of 1.5 (0.5; 5) 
years but one of the lowest HRQoL scores. In accordance with this, an 
HRQoL study of patients with symptomatic hand OA or RA showed that both 
groups had lower HRQoL scores than did healthy controls. Hand OA patients 
had SF-36 scores similar to those of RA patients as to pain, vitality, and social 
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functioning but better scores in measures of physical health (Slatkowsky-
Christensen et al. 2007). Another study of OA patients in a primary care 
setting concluded that patients with OA are less limited in their mobility but 
appear to suffer from an equivalent pain intensity as do patients with RA 
(Rosemann et al. 2007). 
 
We found that conservative treatment failed to improve the HRQoL of OA 
patients in 8 months of follow-up. This is in accordance with the natural course 
of OA that can have a progression rate of 4% per year (Felson et al. 1995). 
The pharmacological treatment of OA patients includes NSAIDs and 
glucosamine products. A recent Cochrane review on the effectiveness of 
glucosamine in OA patients showed a 28% improvement in pain (change from 
baseline) and a 21% improvement in function based on the Lequesne index; 
the results of different studies were, however, not uniformly positive (Towheed 
et al. 2005). The same review failed to show improvement in the pain, 
function, and stiffness index of the Western Ontario and MacMaster 
Universities OA Index (WOMAC) that is an OA-specific health status 
instrument (Bellamy et al. 1988). On the other hand, RCTs of NSAIDs have 
shown at least short-term improvement in HRQoL of OA patients (Lisse et al. 
2001, Zhao et al. 1999). A risk for serious adverse events, however, limits the 
long-term use of NSAIDs. The only treatment method that has shown a 
significant improvement in HRQoL in OA patients is hip or knee joint 
replacement (Norman-Taylor et al. 1996, Escobar et al. 2007).  
 
 
6.2 Early improvement in the HRQoL of RA patients during their first 
anti-TNF treatment 
 
The HRQoL of our RA patients had already improved significantly after 12 
weeks of treatment with etanercept or adalimumab. Improvement in HRQoL 
with both biologicals was equal and paralleled clinical outcome variables. 
 
Several RCTs have assessed the HRQoL of RA patients in subgroup 
analyses. In an RCT of etanercept, HRQoL was measured with the SF-36 in a 
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subgroup of 48 RA patients, with the scores for physical and mental 
components calculated. Both scores improved significantly after 26 weeks of 
treatment with etanercept 25 mg twice weekly (Mathias et al. 2000). Exactly 
the same follow-up time was used in RCT of adalimumab, where again 
significant improvement in HRQoL was observable (Mittendorf et al. 2007). A 
recent study of patients with early RA treated with adalimumab already 
showed improvement in physical domains of the SF-36 after 12 weeks of 
treatment (Kimel et al. 2008). In our study of adalimumab and etanercept, our 
follow-up time was identical, but the patients had long-standing severe RA 
and were treated in routine practice. Despite this we were able to demonstrate 
rapid improvement in HRQoL as measured by RAND-36.  
 
In longitudinal studies of RA patients treated with DMARDs, the HAQ has 
shown a tendency toward a slight increase with time. In a 5-year follow-up 
study of 863 RA patients and 1176 population controls, the increase in HAQ in 
both groups was 0.01 units per year, an increase primarily attributable to the 
age-group over 70 (Sokka et al. 2006). In our study of RA patients treated with 
biologicals, their HAQ scores improved statistically significantly in the 
etanercept group with a median (IQR) change of 0.25 (0.12 to 0.5). In the 
adalimumab group the improvement of the HAQ by 0.25 (0.13; 0.6) was not 
statistically significant, but the change was clinically important. In a study of 
pooled data of 36 trials (Aletaha and Ward 2006), authors showed that 
patients with late RA show less improvement in the HAQ as response to 
treatment than do patients with early RA. They explained the lesser 
improvement in disability by the irreversible nature of joint damage. Therefore, 
we assume that the HAQ results of our study of patients with long-standing 
RA would have been even better had biologicals been started during its early 
phase.  
 
Etanercept and adalimumab were equally effective in our RA patients in 
improving their HRQoL and clinical variables. The best way to compare the 
efficacy of two biologicals would be a randomized head-to-head study. Until 
now, no such study has been performed, so observational studies may be the 
only source of information for that kind of comparison. A recent register study 
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compared the effectiveness and medication costs of three biologicals: 
infliximab, etanercept, and adalimumab given in routine settings (Kievit et al. 
2008). The authors concluded that improvements in the physical component 
scale of SF-36 and in DAS-28 were statistically more pronounced in patients 
treated with adalimumab and etanercept than in those treated with infliximab. 
One possible reason for the worse outcome of patients treated with infliximab 
was the use of the lowest possible dose, 3 mg/kg, in 80% of these patients.  
At the same time, treatment with infliximab resulted in higher medication 
costs.  Etanercept and adalimumab were equally effective in improving the 
SF-36 physical scale, paralleling our own results. 
 
 
6.3 Clinical outcome and costs of treating chronic arthritis patients 
with infliximab  
 
We showed that treatment with infliximab improves the clinical outcome of 
patients with chronic arthritis significantly in routine clinical practice. On the 
other hand, infliximab raised medical costs substantially, and work disability 
costs failed to decrease. 
  
Only a few studies have analysed the costs of using biological drugs in routine 
practice. Our results differ from those of a study conducted in southern 
Sweden (Kobelt et al. 2004) with 160 RA patients treated either with 
etanercept or infliximab in which the direct costs fell by 40% during the first 
year. Several differences between our studies should be noted. First of all, in 
the Swedish study the costs of those 44 patients who discontinued before 
completing one year of treatment were excluded from the direct costs, as 
were also the costs of biologicals. In our study both of those costs are 
included in the analyses. In addition, in the Swedish study, 70% of patients 
were treated with etanercept, which is associated with lower administration 
costs than is infliximab. All of our patients were treated with infliximab. The 
total costs increased in the Swedish study by €12 183 (44%), rising from a 
mean of €27 447 to €39 630; this is comparable to our figures. As expected, in 
neither of the studies did the indirect costs change during one year of follow-
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up. This can be explained by severity of RA, long disease duration, short 
follow-up, and by the fact that approximately 50% of the Swedish patients and 
ours were already on long-term sick-leave (Kobelt et al. 2004). A recent study 
by Kievit et al (2008) evaluated the clinical outcome and medication costs of 
patients treated with infliximab, etanercept, and adalimumab. This register-
based study showed that the medication costs of patients treated with 
infliximab were significantly higher than in patients treated with etanercept and 
adalimumab (Kievit et al. 2008).  
 
Another approach to study the costs of biologicals is to use various models in 
the calculations. Such is the Dutch study by Nuijten et al (2001), in which the 
medical costs of patients treated with etanercept or infliximab were compared 
in a model. They concluded that etanercept was, from a health economics 
standpoint, superior to infliximab. But we have to take into account that the 
perspective of this study was that of Dutch society, and results of economic 
modeling studies cannot be easily transferred to other societies (Welte et al. 
2004).  
 
The reasons for higher costs for patients treated with infliximab can be the 
route of administration and the loading dose.  Administration of infliximab 
intravenously requires visits to a medical specialist, while etanercept and 
adalimumab can be injected at home. In addition, infliximab treatment is 
started with a loading dose that raises the costs in the first year of use. For us, 
as well, costs for infliximab administration in addition to the price of infliximab 
raised the medical costs substantially. 
 
 
6.4 Clinical impact of switching from infliximab to etanercept in 
patients with RA  
 
In 49 RA patients, treatment with infliximab was discontinued and etanercept 
started for three reasons: infliximab failure, adverse event, or non-medical 
reasons. We were able to demonstrate that switching from established 
infliximab therapy to etanercept in the non-medical-reasons group was well 
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tolerated, and the good response was maintained. A similar result occurred 
with switching from infliximab to adalimumab in RA patients who have 
responded well to infliximab in a small open-label study in Ireland (Walsh et al. 
2007). This was a study of 19 patients who were treated with infliximab for at 
least 12 weeks and responded to the treatment well; they were willing to 
switch to treatment with self-administered injections of adalimumab. The 
authors concluded that switching to adalimumab was safe and well tolerated 
and no significant changes in the HRQoL or physical function were detectable 
after the switch.  
 
Although switching between etanercept, adalimumab, and infliximab has not 
been studied in any RCTs, several small observational studies have shown 
that, in the case of infliximab failure or adverse event, switching RA patients 
between biologicals can be an effective and safe option (Buch et al. 2007, 
Nikas et al. 2006, van Vollenhoven et al. 2003, Haraoui et al. 2004, Sanmarti 
et al. 2004, Hansen et al. 2004, Wick et al. 2005, Cohen et al. 2005). In our 
study, as well, the DAS28 score improved significantly in those whose reason 
to switch from infliximab to etanercept was infliximab failure or adverse event.  
 
Several large register-based studies on treatment of RA patients with TNF-
inhibitors have appeared lately. A recent study from the South Swedish 
Arthritis Treatment Group Register demonstrated that the response rates of 
the first-time anti-TNF switchers were lower than the response rates in anti-
TNF-naïve patients, and furthermore, that the response rates of second-time 
switchers were markedly lower. They also showed that younger age, lower 
HAQ score, and higher DAS28 at baseline predicted better response to 
second-line treatment (Karlsson et al. 2008).  
 
 In a large prospective cohort study, 73% of patients who switched to a 
second anti-TNF agent had remained on the new therapy by the end of the 
mean follow-up of 6 months (Hyrich et al. 2007). Another register-based study 
reported that the drug survival rate after the switch to a second anti-TNF is 
significantly lower than for the first course of anti-TNF, and that drug survival 
was statistically significantly lower for infliximab (34%) than for etanercept 
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(76%), or adalimumab (67%) (Gomez-Reino et al. 2006). The second anti-
TNF survival in our study was significantly lower than in the earlier studies. In 
the group of infliximab failure, the 1-year drug survival was 43% (95% CI, 26 
to 70) and in the adverse event group 50% (95% CI, 33 to 100).  Only in the 
group involving non-medical reasons was the 1-year drug survival after the 
switch higher, 77% (95% CI, 62 to 97).  
 
A new approach for treating patients with an inadequate response to TNF-
inhibitors is to switch to B-cell-depleting therapy with rituximab (RTX). This 
was assessed in a cohort study of 116 RA patients who had an inadequate 
response to at least 1 TNF-inhibitor and in whom switching to an alternative 
TNF-inhibitor was compared with switching to RTX (Finckh et al. 2007). 
Compared to those 66 patients who received another course of TNF-inhibitor, 
the evolution of DAS28 in those 50 patients who received RTX was more 
favourable (p=0.01). The authors concluded that treatment with RTX could be 
a better alternative in patients with a first or second inadequate response to a 
TNF-inhibitor than the use of all other alternative TNF-inhibitors. In addition, 
that study showed that one of the predictors of favourable outcome was the 
use of concomitant DMARDs. 
 
In Studies I and II, we used the questionnaires RAND-36, 15D, and HAQ to 
measure patient-reported outcomes of treatment. Patient questionnaires have 
proven better than any laboratory test or imaging method in predicting 
important clinical outcomes of RA such as mortality and work disability 
(Pincus et al. 1984, Wolfe & Hawley 1998). They could therefore prove useful 
not only in clinical research but also for patient follow-up in routine practice. 
However, these questionnaires are so long and complicated that in the busy 
schedule of routine visits they are rarely used. Several shorter and easier 
questionnaires based on the HAQ have been developed in recent years such 
as the modified HAQ (MHAQ), multidimensional HAQ (MDHAQ), HAQ-II, and 
Routine Assessment of Patient Index Data 3 (RAPID3) that could be 
incorporated into the routine follow-up of individual patients (Pincus et al. 
2005, 2008, Wolfe et al. 2004).        
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6.5 Strengths and limitations of the study (I-IV) 
 
In large RCTs, the efficacy of treatments is evaluated in the ideal setting of 
selected patients.  The strength of all our studies is that we assessed the 
effectiveness of treatments in routine circumstances in unselected patients.  
 
All the patients in the present studies (I-IV) were gathered from the Helsinki 
University Central Hospital and from the Lappeenranta Central Hospital (II). 
Because patients with more severe diseases are treated in central or 
university hospitals, results cannot be generalized to all patients with the 
same diseases. However, because patients with severe diseases that need to 
be treated with biologicals are mostly directed to central hospitals, our data 
therefore most likely reflect the routine care setting in the treatment of arthritis 
patients with biologicals (II-IV).  
 
A limitation in Study I was a low level of response to the first questionnaire 
(57%) and a high number of drop-outs (23%) on follow-up. 
  
In Study III, costs were compared in a setting of one year before and one year 
during treatment with infliximab without any concurrent comparison group. In 
addition, that not all relevant costs are included in the analyses can be 
considered a weakness of that study. 
 
In all our studies, the number of patients as a whole (II-IV) or in diagnostic 
groups (I) was small; this can also be considered a limitation. 
 75 
SUMMARY AND CONCLUSIONS 
 
In conclusion, effective treatment either with combinations of DMARDs or with 
TNF-inhibitors improves both clinical parameters and the HRQoL of patients 
with RA, improving their long-term outcome. In the case of unresponsiveness 
to the first TNF-inhibitor, a switch to the next one is the routine practice. The 
clinical effectiveness of switching has been demonstrated in small 
observational studies, and the same result was observed here. Furthermore, 
we could demonstrate that patients who have responded well to infliximab 
could be switched to etanercept without losing their drug response. Such a 
switch can prove useful in situations in which a patient is unable or unwilling to 
come to the hospital for infliximab infusions.  
 
We also have shown that the one-year treatment with infliximab in routine 
practice saves neither medical nor work-disability costs. Further research 
should demonstrate whether any saving will be achieved in patients treated 
with biologicals in the earlier phase of the disease. These finding imply the 
necessity of developing a treatment for those RA patients who fail to respond 
to any TNF-inhibitors or to other biologicals.   
  
We demonstrated the low HRQoL of patients with rheumatic diseases referred 
to the rheumatology clinic compared to that of the age-adjusted general 
population. HRQoL was lower not only in patients with chronic inflammatory 
joint diseases but also in patients with OA and arthralgia and fibromyalgia. 
The HRQoL improved significantly with conventional treatment in patients with 
RA and ReA. However, the current pharmacological treatment failed to 
improve the HRQoL of OA patients during the 8-month follow-up. Further 
research is necessary to assess the HRQoL of patients with differing 
diagnoses in routine care during longer periods of time.  
 
Etanercept and adalimumab treatment had already improved significantly the 
HRQoL of our RA patients in the first 3 months. Despite the longstanding RA 
with its mean duration of 17 years, the improvement in HRQoL was 
significant. Another research implication would be to follow patients treated 
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with biologicals for longer periods to analyse whether the improvement of 
HRQoL will persist and how will it affect their long-term outcome.   
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